<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Mol Med</journal-id><journal-title-group><journal-title>Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1076-1551</issn><issn pub-type="epub">1528-3658</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410684</article-id><article-id pub-id-type="pmc">PMC12100796</article-id><article-id pub-id-type="publisher-id">1260</article-id><article-id pub-id-type="doi">10.1186/s10020-025-01260-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mucosal implications of oral Jak3-targeted drugs in COVID patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kumar</surname><given-names>Narendra</given-names></name><address><email>narendra08@tamu.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Segovia</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Priyam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Atti</surname><given-names>Hima Bindu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Soaham</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mishra</surname><given-names>Jayshree</given-names></name><address><email>Jayshree.mishra@tamu.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01f5ytq51</institution-id><institution-id institution-id-type="GRID">grid.264756.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4687 2082</institution-id><institution>ILR-College of Pharmacy, </institution><institution>Texas A&#x00026;M University Health Science Center, </institution></institution-wrap>Kingsville, TX USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b30xv10</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff3"><label>3</label>Veterans Memorial High School, Corpus Christi, TX USA </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>31</volume><elocation-id>203</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The JAK family, particularly JAK3, plays a crucial role in immune signaling and inflammatory responses. Dysregulated JAK3 activation in SARS-CoV-2 infections has been associated with severe inflammation and respiratory complications, making JAK inhibitors a viable therapeutic option. However, their use raises concerns regarding immunosuppression, which could increase susceptibility to secondary infections. While long-term adverse effects are less of a concern in acute COVID-19 treatment, patient selection and monitoring remain critical. Furthermore, adverse effects associated with oral JAK3 inhibitors necessitate the exploration of alternative strategies to optimize therapeutic efficacy while minimizing risks. This review highlights the role of JAK3 in immune and epithelial cells, examines the adverse effects of oral JAK3 inhibitors in COVID-19 and other treatments, and discusses alternative therapeutic strategies for improving patient outcomes.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s10020-025-01260-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Keyword 1</kwd><kwd>Covid-19</kwd><kwd>Keyword 2</kwd><kwd>Jak3</kwd><kwd>Keyword 3</kwd><kwd>Mucosal -epithelial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="Sec2"><title>Current state of COVID virus</title><p id="Par2">COVID-19 has been responsible for a worldwide epidemic since December 2019 and poses a worldwide medical threat. Individuals&#x02019; top respiration illnesses, fever, and serious pneumonia are caused by the extremely virulent encapsulated positive-strand RNA virus known as severe acute respiration syndrome coronavirus 2 (SARS-CoV-2). The virus uses host assets at every phase of its life cycle (Alam et al. <xref ref-type="bibr" rid="CR1">2021</xref>) and cellular kinase is necessary for their existence. In coronavirus diseases, these kinases are related to inflammatory processes, fibrosis, and signs like pneumonia and moreover spreading of the corona virus. Kinase inhibitors are, therefore, helpful in the fight against disease or epidemic since they have antibacterial, anti-inflammatory properties, anti-cytokine, and anti-fibrotic properties (Alam et al. <xref ref-type="bibr" rid="CR1">2021</xref>; Parvathaneni and Gupta <xref ref-type="bibr" rid="CR91">2020</xref>). Approximately between 25 and 30% of new drugs created by medical firms concentrate on protein kinases. Numerous potential kinase inhibitors helped the serious and sometimes fatal signs of COVID-19 (Bellera et al. <xref ref-type="bibr" rid="CR8">2021</xref>; Indari et al. <xref ref-type="bibr" rid="CR44">2021</xref>). Kinase inhibitors are used to reduce medical symptoms and immediately attack the infectious agent to avoid disease. Kinases are additionally employed to increase the effectiveness of specific SARS-CoV-2 therapies and investigations are still currently being conducted to determine the efficacy of the kinase inhibitors as an effective treatment (Chakraborty et al. <xref ref-type="bibr" rid="CR17">2021</xref>).</p></sec><sec id="Sec3"><title>COVID virus &#x00026; tyrosine kinase signaling</title><sec id="Sec4"><title>Tyrosine kinases in viral entry and replication</title><p id="Par3">AXL is a tyrosine kinase (TK) found on the cell membrane that regulates immune systems, development, division, and cell replication. Vitamin-K-reliant GAS-6 (amino acids development arrest-particular gene 6) is one ligand that activates AXL (Chakraborty et al. <xref ref-type="bibr" rid="CR17">2021</xref>). This simulates several subsequent signaling routes, like RAS/ERK, NF-B, p38, etc. AXL kinase was essential to COVID-19, allowing the virus to enter and influencing the antiviral activity of human Sertoli cells. SARS-CoV-2 uses AXL as a substitute receptor. By employing proteome techniques to analyze SARS-CoV-2 rise proteins that bind from cells lacking ACE2, it is possible to identify AXL. Three separate methods were used to determine the involvement of AXL in viral entry: adding AXL to AXL-negative HEK293 T cells, which allowed invasion; employing dissolved AXL to prevent virus; and breaking out AXL in ACE2-negative AXL-high cells, which prevented transmission. AXL transcription is significantly greater than ACE2 levels in respiratory and bronchi epithelium membranes. AXL's role in regulating SARS-CoV-2 disease is probably distinct from ACE2, as evidenced by the fact that it never shared with ACE2 or TMPRSS2 in the lungs or trachea, that downregulating AXL in ACE2-KO cells substantially lowered SARS-CoV-2 pseudo disease, and that never AXL nor ACE2 could prevent virus entry when the additional protein was overstated. Since SARS-CoV-2 binding, internalizing, and disease were significantly decreased but not eliminated in AXL-KO H1299 cells, there may be additional receptors besides AXL and ACE2 that control viral entry (Branco et al. <xref ref-type="bibr" rid="CR11">2020</xref>). Non-receptor TKs (NRTKs) are intracellular cytoplasm structures that are either nuclear-based or attached to the cell surface and transmit intracellular impulses. In cell signaling, NRTKs exhibit a wide range of functions. This involves controlling gene activity, for instance, by phosphorylating the membrane-based Janus kinase (JAK) with IL-6, which activates the signal transduction and activation of transcriptional (STAT) in COVID-19 (Shanker et al. <xref ref-type="bibr" rid="CR111">2024</xref>). The primary downward mechanism of type I IFN activity following viral replication involves the JAK-STAT signaling system, and a malfunction in this route was a key factor in the viral immunological evasion from routine immune monitoring. Few studies have examined the connection between COVID-19 and elevated ACE2 and JAK-STAT route transcripts. According to these findings, increased ACE2 levels may trigger the JAK-STAT signaling routes, which would alter the immunological system following an illness with SARS-Cov. More notably, the strong link between ACE2 &#x00026; JAK-STAT signaling throughout the COVID-19 disease analysis was directly demonstrated by the above relationship involving ACE2 &#x00026; IFN-JAK-STAT signaling being confirmed in a separate cell related to SARS-Cov and SARS-Cov-2 disease (Satarker et al. <xref ref-type="bibr" rid="CR110">2021</xref>).</p></sec><sec id="Sec5"><title>Impact on immune response and cytokine storm</title><p id="Par4">IL-6 has been shown to play an important role in the cytokine release syndrome (CRS) in the JAK-STAT signaling route, conferring a variety of biological activities. As previously stated, cytokines are high in COVID-19 patients, and these cytokines are recognized to perform an important part in the initiation of ARDS. This demonstrates that suppressing the cytokine storm through the JAK-STAT signaling route may be a potential strategy to enhance existing COVID-19 medical treatment options (Amini-Farsani et al. <xref ref-type="bibr" rid="CR4">2021</xref>). Several anti-inflammation cytokines are produced through the Bruton TK (BTK) route, and blocking BTK signaling lowers cytokines, which in turn has an anti-inflammation impact. It plays a part in mast cell activity through the high-affinity immunoglobulin E receptor. One important pathologic element of SARS-CoV-2 lung damage could involve defects in the control of the BTK signal in lung cells. Thus, blocking the BTK route may lessen the serious type of COVID-19's overactive and damaging immune response as well as the breathing issues that arise from it (McGee et al. <xref ref-type="bibr" rid="CR80">2021</xref>). The SARS-CoV-2 S and E proteins are ligands for TLR2, which binds to TLR1 and TLR6 to create heterodimers for signaling via TRIF and MyD88 (Zheng et al. <xref ref-type="bibr" rid="CR141">2021</xref>). To produce inflammation-related compounds, TLR2 regulates the stimulation of the NF-&#x003ba;B route. Two further investigations showed the binding location of SARS-CoV-2 S protein to TLR4, while computerized research indicated that SARS-CoV-2 S protein might bind effectively to TLR4. The viral S1 segment activates the NF-&#x003ba;B and mitogen-activated protein kinases (MAPK) routes, which have been linked to macrophage immunity stimulation.</p></sec><sec id="Sec6"><title>Tyrosine Kinase Inhibitors (TKIs) as potential therapeutics</title><p id="Par5">The possible use of baricitinib (JAK inhibitor) in the treatment of COVID-19 individuals (Spinelli et al. <xref ref-type="bibr" rid="CR121">2020</xref>; Cantini et al. <xref ref-type="bibr" rid="CR14">2020</xref>) conducted a pilot trial to examine the security and effectiveness of baricitinib treatment in 12 individuals with mild COVID-19. Individuals acquiring baricitinib showed higher clinical enhancements, with no infectious or hematologic complications noticed until 2&#x000a0;weeks afterward, resulting in medical professionals suggesting that short-term baricitinib application (1&#x02013;2 weeks) is less probable to encourage important illness but could be capable of minimizing viral reproduction and the abnormal host inflammation action on medical dosage. Acalabrutinib (BTK inhibitor) was used in an observational trial by Roschewski, et al. (<xref ref-type="bibr" rid="CR105">2020</xref>) on 19 inpatients who required extra oxygen because of serious COVID-19. After 10 to 14 days, most of the people who received treatment saw their inflammatory biomarkers revert to routine. Of 11 people who required additional oxygen, eight (72.7%) were able to breathe satisfactorily on room air after therapy. Out of eight individuals, 4 (50%) required ventilator-assisted exhumation. Lastly, after their medical care, twenty-five percent of intubated individuals inhaled freely in ambient air with no notable adverse outcomes. TKIs target protein kinases, although they typically disrupt several kinases (~ 10&#x02013;100), increasing the potential for toxicity. Previous investigations found that approximately 5% of patients stopped using imatinib or multi-kinase inhibitors (MKIs) because of TKI-related side effects (Jacobs et al. <xref ref-type="bibr" rid="CR45">2021</xref>). Nevertheless, it is critical to recognize the strong link between therapeutic efficacy and the incidence of adverse responses. The adverse reaction characteristic is commonly employed as a tracking instrument to determine the intended results of cancer treatment. Nevertheless, a positive association was found between the percentage of kinases hindered and the level of their hazardous capacity.</p></sec></sec><sec id="Sec7"><title>COVID virus &#x00026; non-tyrosine signaling</title><sec id="Sec8"><title>Serine/threonine kinase pathways in SARS-CoV-2 infection</title><p id="Par6">A vital cell signaling route, the PI3 K/Akt/mTOR route controls several cell functions, including anabolism, nutrition intake, cell development, distinction, existence, proliferating, and movement. This has contributed to the theory that SARS-CoV-2 disease could be improved by either one or two inhibitors of this route. The authorized use of PI3 K, Akt, and mTOR individual inhibitors is for the therapy of various illnesses, mostly but not solely neoplasm. While some combo inhibitors are in clinical testing, just a limited number have received approval for medical usage (Basile et al. <xref ref-type="bibr" rid="CR6">2022</xref>). Numerous cellular functions depend on intracellular signaling routes that are controlled by MAPKs. The MAPK class in animals primarily consists of p38 MAPKs, c-Jun N-terminal kinases, and external signal-controlled kinases. Certain external stimuli trigger the MAPK pathway action, which involves the successive activity of MAPK kinase and MAPK kinase (MAPKKK), which in turn triggers the release of certain MAPK. In addition to SARS-CoV disease, the p38 MAPK route was linked to inflammation damage in COVID-19 sufferers'hearts and lungs (Roy et al. <xref ref-type="bibr" rid="CR106">2021</xref>).</p></sec><sec id="Sec9"><title>AMPK and other kinases in host response</title><p id="Par7">An intracellular serine/threonine kinase called AMPK plays a crucial role in regulating metabolism and preserving cellular power. By altering cellular metabolism to produce power via catabolic routes like glucose absorption and by inhibiting unnecessary anabolic activities like protein, lipid, and carbohydrate production, AMPK is triggered by metabolism strain and works to maintain power equilibrium (Huang et al. <xref ref-type="bibr" rid="CR43">2022</xref>). The PKA and PKC routes are two of the signaling mechanisms that control the synthesis of IL-6. PKC inhibitors decrease SARS-CoV-2 growth in BHK-21 cells. A SARS-CoV-2 replica, which contains virus NS proteins linked through a nano luciferase, was employed to replace the architectural proteins and several auxiliary proteins to investigate if PKC inhibitors impact SARS-CoV-2 replicating. PKC inhibitors work at the starting point of the replicating of SARS-CoV-2. The kinetic luciferase activity of the replication in BHK-21 cells was observed to ascertain the stage at which the PKC inhibition works (Huang et al. <xref ref-type="bibr" rid="CR43">2022</xref>).</p></sec></sec><sec id="Sec10"><title>Crosstalk between tyrosine and non-tyrosine kinase pathways during covid infection</title><p id="Par8">The JAK/STAT and PI3 K/AKT/mTOR routes are the primary signaling processes for numerous development variables and cytokines, and their activation promotes cell proliferation, distinction, movement, and death. Nevertheless, numerous malignancies, such as leukemia, have continuous activation of the JAK/STAT and PI3 K/AKT/mTOR routes because of inherited occurrences like cytokine receptor alterations and abnormal chromosomal transfers. C-Myc was overproduced by continuous activity of the JAK/STAT and PI3 K/AKT signaling routes (Mahjoor et al. <xref ref-type="bibr" rid="CR76">2023</xref>). As a dual-targeting treatment for COVID-19, reseparate reduces virus transmission and inhibits macrophage-mediated proinflammatory immunity (Mishra et al. <xref ref-type="bibr" rid="CR86">2017</xref>). Rone-parstat's secure patient characteristics and dual-targeting impact on virus disease and macrophage-triggered inflammation cytokine discharge may be helpful in this situation. To sum up, the preliminary evidence indicates that heparinase is a focus for the pathophysiology of SARS-CoV-2 and that Reseparate may be a potential dual-targeting drug for COVID-19. Given the enormous role of mucosal Jak3 in inflammation, the present article highlights the importance of Jak signaling during different stages of COVID-19 infections and the essential roles of mucosal epithelial Jak3 which are anatomically juxtaposed to the immune cell Jak3, in COVID pathogenesis (Kumar et al. <xref ref-type="bibr" rid="CR57">2021</xref>). Jak inhibitors are mostly oral (Li et al. <xref ref-type="bibr" rid="CR68">2022</xref>) and encounter lung and/or intestinal mucosal epithelial cells first before targeting immune cell Jak3 inhibition and taming the cytokine storm. Our group has extensively worked on mucosal epithelial Jak3 including its role in intestinal restitution and redifferentiation of mucosal epithelial cells following restitution not to mention its role in epithelial mesenchymal transition, cell homeostasis, and barrier function restoration (Kumar et al. <xref ref-type="bibr" rid="CR57">2021</xref>; Kumar et al. <xref ref-type="bibr" rid="CR56">2007</xref>; Kumar et al. <xref ref-type="bibr" rid="CR58">2022</xref>; Mishra et al. <xref ref-type="bibr" rid="CR87">2019</xref>; Mishra et al. <xref ref-type="bibr" rid="CR86">2017</xref>; Mishra et al. <xref ref-type="bibr" rid="CR85">2013</xref>). As a part of the scientific community, it is important to discuss and understand the functional consideration for mucosal epithelial-specific Jak3 and their consequences in designing and developing the Jak3 or JAK-STAT signaling targeted drugs for reducing cytokine storm to combat covid. Based on published literature and current understanding on the emerging roles of mucosal epithelial Jak3 functions, additional preliminary data are provided on constant communication and crosstalk between mucosal epithelial Jak3 and immune cell Jak3 in covid pathogenesis that can shed new lights on Jak3-mediated interventions. Additionally, the implications of Jak3-domain structures other than those of the kinase domain are also discussed in context of targeted interventions for the emerging variants of COVID through rational drug designing.</p></sec><sec id="Sec11"><title>Covid drugs targeting cytokine cascade</title><p id="Par9">A growing body of clinical data suggests that a cytokine storm is an excessive immune response associated with COVID-19 severity and the main cause of death from COVID-19 (Ye et al. <xref ref-type="bibr" rid="CR136">2020</xref>). A key player in this process is interleukin-6 (IL-6), a pro-inflammatory cytokine and targeting this key player and treatment of the cytokine storm are important components for rescuing patients with severe COVID-19. In COVID-19, elevated levels of IL-6 contribute to the hyperinflammatory state observed in cytokine storms. At the molecular level, IL-6 binds to its receptor (IL-6R), forming a complex that interacts with the signal transducer gp130, leading to the activation of inflammatory pathways (Li et al. <xref ref-type="bibr" rid="CR66">2023</xref>). Evidence suggests that the hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19 (Li et al. <xref ref-type="bibr" rid="CR66">2023</xref>). For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-6 inhibitors, interleukin-1 blockers, Janus kinase inhibitors, in COVID-19. Tocilizumab is a humanized monoclonal antibody that targets the IL-6 receptor (IL-6R), thereby inhibiting IL-6-mediated signaling (Ali et al. <xref ref-type="bibr" rid="CR3">2020</xref>). Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Although with limitations of a single-arm study, performed in an extremely challenging time and environment, use of tocilizumab, even when corticosteroids are used, while waiting for publication of phase 3 results. Administration of tocilizumab has been linked to a decrease in mortality rates among patients exhibiting high levels of IL-6 and requiring oxygen support. The effectiveness of tocilizumab may depend on the timing of its administration, with earlier intervention during the hyperinflammatory phase potentially yielding better outcomes (Piccirillo et al. <xref ref-type="bibr" rid="CR93">2020</xref>; Leaf et al. <xref ref-type="bibr" rid="CR61">2021</xref>; Chiodini et al. <xref ref-type="bibr" rid="CR19">2020</xref>). Canakinumab, a human monoclonal antibody targeting interleukin-1 beta was used to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir) (Leaf et al. <xref ref-type="bibr" rid="CR61">2021</xref>; Ucciferri, et al. <xref ref-type="bibr" rid="CR128">2020</xref>; Falasca et al. <xref ref-type="bibr" rid="CR29">2021</xref>). In hospitalized adult patients with mild or severe non-ICU COVID-19, canakinumab is a valid therapeutic option as Canakinumab therapy caused rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events. Finally, Janus kinase (JAK) inhibitors, which may have a role in blocking the fibrotic evolution in some patients, are being evaluated (Mahjoor et al. <xref ref-type="bibr" rid="CR76">2023</xref>). The JAK/signal transducers and activators of transcription STAT-pathway mediates the signaling of multiple cytokines, therefore interrupting this pathway may be an attractive strategy to modulate the immunopathology observed in SARS-CoV-2 infection (Satarker et al. <xref ref-type="bibr" rid="CR110">2021</xref>). Besides, many JAK inhibitors exhibit antiviral effects when administered at therapeutic doses, by targeting host factors that viruses use for cell entry (Jain et al. <xref ref-type="bibr" rid="CR46">2023</xref>). Baricitinib is an oral JAK inhibitor, that inhibits the JAK signal transducer and activator of transcription pathway which are under investigation in some clinical trials on COVID-19 patients. A pilot study from Italy showed a significantly improvement in clinical and laboratory parameters in patients treated with baricinib (Singh, et al. <xref ref-type="bibr" rid="CR115">2021</xref>) Ruxolitinib, another JAK-kinase inhibitor, showed in COVID19 patients with hyperinflammation, to be safe and prevent multiorgan failure (Han et al. <xref ref-type="bibr" rid="CR40">2022</xref>; Weinstein et al. <xref ref-type="bibr" rid="CR131">2025</xref>; Ucciferri et al. <xref ref-type="bibr" rid="CR127">2020</xref>).</p></sec><sec id="Sec12"><title>Genetic variations in JAK and COVID-19 severity and susceptibility</title><p id="Par10">Genetic variations in human host genes play a significant role in susceptibility, severity, and outcomes of, infectious diseases&#x02014;including COVID-19. Among the most critical pathways involved in host immune response is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling cascade. This evolutionarily conserved pathway is activated by a range of cytokines, interferons, and growth factors, serving as a central mediator of immune regulation (Rao et al. <xref ref-type="bibr" rid="CR100">2023</xref>). Functionally, relevant mutations and polymorphisms in JAK family proteins, including TYK2, JAK1, JAK2, and JAK3, have been associated with diverse immune-related diseases and have now been implicated in COVID-19 severity and susceptibility (Kosmicki et al. <xref ref-type="bibr" rid="CR54">2024</xref>; Singh et al. <xref ref-type="bibr" rid="CR113">2021</xref>). The clinical relevance of the pathway is underscored by the development of a new class of targeted therapeutics&#x02014;JAK inhibitors&#x02014;currently in use for inflammatory diseases and under investigation for COVID-19 treatment. Recent studies have identified specific variants of Tyk2 associated with COVID-19 outcomes. TYK2 p.Gly363Ser and STAT2 p.Met594Ile have been linked to increased susceptibility to SARS-CoV-2 infection (Benmansour et al. <xref ref-type="bibr" rid="CR9">2024</xref>; Jiang et al. <xref ref-type="bibr" rid="CR47">2023</xref>; Castro et al. <xref ref-type="bibr" rid="CR25">2025</xref>). Genome-wide association studies (GWAS), including data from the COVID-19 Host Genetics Initiative, have demonstrated that loss-of-function mutations in TYK2 are protective against severity disease. TYK2 is critical in type I interferon (IFN) and IL-12 signaling; thus, its inhibition may reduce hyperinflammatory responses such as cytokine storms which positions TYK2 inhibitor<bold>s</bold> as promising dual-purpose therapeutics&#x02014;attenuating inflammation while minimizing the risk of immune suppression (Guo et al. <xref ref-type="bibr" rid="CR37">2022</xref>). Further bioinformatic analyses have highlighted the potential role of rare variants in interferon receptor genes IFNAR1 p.Val168Leu, is associated with a reduced risk of severe COVID-19, while rare pathogenic variants in both IFNAR1 and IFNAR2 may impair antiviral signaling. Other JAK family members also play essential roles in immune regulation. While JAK1 and JAK3 have been less prominently implicated in GWAS, their roles remain biologically significant. JAK1 is indispensable for type I IFN signaling, and functional defects could impair viral clearance (Hasselbalch et al. <xref ref-type="bibr" rid="CR42">2021</xref>; Hammersen et al. <xref ref-type="bibr" rid="CR39">2023</xref>). Gain-of-function mutations like JAK2 V617 F result in constitutive activation of the pathway and may exacerbate hyperinflammatory responses, thereby worsening COVID-19 pathology (Elbadry et al. <xref ref-type="bibr" rid="CR28">2022</xref>; Pelkey et al. <xref ref-type="bibr" rid="CR92">2022</xref>). JAK3, primarily expressed in immune cells, is associated with immunodeficiency syndromes, which may influence COVID-19 outcomes depending on the inflammatory context. Similarly, mutations in MPL associated with Myeloproliferative neoplasms (MPNs) (e.g., W515L/K/A) and deletions in LNK, a negative regulator of JAK-STAT signaling, contribute to aberrant pathway activation, with potential consequences for disease severity (Lucijanic et al. <xref ref-type="bibr" rid="CR73">2021</xref>; Harrington et al. <xref ref-type="bibr" rid="CR41">2021</xref>). So, host genetic variation in the JAK-STAT signaling axis&#x02014;particularly in TYK2, IFNAR1/2, and JAK2&#x02014;profoundly influences COVID-19 susceptibility and severity that lays the groundwork for not only personalized therapeutic strategies, including early immunomodulation tailored to patients with pro-inflammatory JAK variants but also for impaired antiviral signaling. TYK2 polymorphisms have been linked with autoimmune diseases such as systemic lupus erythematosus (SLE), psoriasis, and multiple sclerosis (MS). A well-studied TYK2 SNP, rs34536443 (P1104 A), is a hypomorphic allele, which decreases IL-12 and IL-23 signaling, conferring protection against autoimmunity but susceptibility to infection (Dendrou, et al. <xref ref-type="bibr" rid="CR26">2016</xref>). STAT3 gain-of-function (GOF) mutations were found to occur in early-onset autoimmunity, lymphoproliferation, and enteropathy. The mutations result in hyperactivation of STAT3-dependent genes, which contributes to immune dysregulation syndromes (Zhou et al. <xref ref-type="bibr" rid="CR144">2016</xref>). STAT1 GOF mutations lead to interference with STAT1 dephosphorylation, leading to enhanced interferon signaling manifests, chronic mucocutaneous candidiasis and autoimmunity. Alternatively, STAT1 loss-of-function leads to enhanced susceptibility to mycobacterial and viral infections (Zhang et al. <xref ref-type="bibr" rid="CR137">2008</xref>).</p></sec><sec id="Sec13"><title>Immune vs mucosal cell Jak3</title><sec id="Sec14"><title>Immune cell Jak3</title><p id="Par11">Is a non-receptor tyrosine kinase of the Janus family, is involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells. Deficiency of Jak3 results in defined clinical disorders, particularly, inactivating Jak3 mutations leads to severe combined immunodeficiency syndrome and has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs. In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small-molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and auto immune diseases.</p></sec><sec id="Sec15"><title>Mucosal functions of Jak3</title><p id="Par12">Jak3 is expressed in non-hematopoietic cells, where it plays crucial roles in mucosal wound repair, cell homeostasis, efflux function, and barrier integrity (Kumar et al. <xref ref-type="bibr" rid="CR57">2021</xref>; Kumar et al. <xref ref-type="bibr" rid="CR56">2007</xref>; Mishra et al. <xref ref-type="bibr" rid="CR84">2012</xref>; Shao et al. <xref ref-type="bibr" rid="CR112">2023</xref>; Momen et al. <xref ref-type="bibr" rid="CR88">2024</xref>). It contributes to mucosal wound healing by reorganizing actin, facilitating epithelial motility through filopodial and lamellipodial extensions in enterocytes (Kumar et al. <xref ref-type="bibr" rid="CR56">2007</xref>). Additionally, Jak3 enhances IL-2-induced villin phosphorylation, promoting gastrointestinal cell wound healing. Intestinal mucosal homeostasis is maintained through a delicate balance of crypt cell proliferation, migration along the crypt-villus axis, differentiation, and eventual apoptotic shedding at the villus tip. IL-2 activates Jak3, which regulates mucosal homeostasis through post-translational and transcriptional mechanisms, including its interaction with the adapter protein p52ShcA (Mishra and Kumar <xref ref-type="bibr" rid="CR83">2014</xref>). Jak3 is also critical for barrier function, adherent&#x02019;s junction (AJ) formation, epithelial-mesenchymal transition (EMT), and colonic polyp development by interacting with and phosphorylating &#x003b2;-catenin (Mishra et al. <xref ref-type="bibr" rid="CR86">2017</xref>). Furthermore, Jak3 influences intestinal drug efflux and barrier integrity through its interaction with and phosphorylation of the efflux protein BCRP (Mishra et al. <xref ref-type="bibr" rid="CR87">2019</xref>). This interaction enhances BCRP&#x02019;s association with membrane-localized &#x003b2;-catenin, which is essential for BCRP expression, surface localization, and efflux functionality.</p></sec></sec></sec><sec id="Sec16"><title>COVID-19 and Jak signaling</title><p id="Par13">Reported first in late 2019 in China, COVID-19 is a respiratory infection caused by SARS-CoV-2, (Zhou, et al. <xref ref-type="bibr" rid="CR143">2020</xref>) The initial symptoms include cold, dry cough followed by sputum, shortness of breath, and dyspnea. However, upon respiratory failure the disease worsening leading to acute respiratory distress syndrome (ARDS) and cytokine storm causing hyperinflammation and even death (Zhang et al. <xref ref-type="bibr" rid="CR138">2022</xref>) The cytokine storm is characterized by increase in pro-inflammatory cytokine including IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, TNF-&#x003b1;, GCS-F, INF-&#x003b3; inducible protein 10, MCP-1, and MIP-1&#x003b1; (Mehta et al. <xref ref-type="bibr" rid="CR81">2020</xref>) The cytokine storm is one of the key event implicated in several of the COVID-19 complications including lung injury, ARDS, acute kidney and cardiac injury leading to multi-organ failure eventually leading to death in COVID-19 patients (Mehta et al. <xref ref-type="bibr" rid="CR81">2020</xref>; Yang et al. <xref ref-type="bibr" rid="CR135">2020</xref>) Among the cytokines, the key prognosis markers are elevated serum levels of IL-6 and IFN-gamma. The high mortality rate has been attributed to cytokine storm led hyperinflammation vascular disorders culminating in pulmonary embolism, cerebral thromboembolism and multisystem failures (Tanaka <xref ref-type="bibr" rid="CR123">2023</xref>). Since Jaks play a pivotal role in majority of cytokine signaling through JAK-STAT pathways in COVID-19 pathophysiology, an understanding of its beneficial and detrimental impacts is warranted.</p><sec id="Sec17"><title>Overview of SARS-CoV-2 and Jak-targeted drugs</title><p id="Par14">The World Health Organization continues to classify COVID-19 as a worldwide pandemic, still with positive cases in the developed and developing countries (Cucinotta and Vanelli <xref ref-type="bibr" rid="CR22">2020</xref>; Solis Arce et al. <xref ref-type="bibr" rid="CR118">2021</xref>; Smith et al. <xref ref-type="bibr" rid="CR116">2020</xref>). Since the beginning of the pandemic, multiple vaccines have been released to prevent COVID-19 (Andrews, et al. <xref ref-type="bibr" rid="CR5">2022</xref>; Chung et al. <xref ref-type="bibr" rid="CR20">2021</xref>; Lopez Bernal, et al. <xref ref-type="bibr" rid="CR72">2021</xref>; Thompson et al. <xref ref-type="bibr" rid="CR125">2021</xref>; Hall et al. <xref ref-type="bibr" rid="CR38">2022</xref>) and many antiviral medications have been developed to reduce the progression of COVID-19 infection, as suggested by clinical and randomized controlled trials (Forchette et al. <xref ref-type="bibr" rid="CR32">2021</xref>; Kumari et al. <xref ref-type="bibr" rid="CR59">2022</xref>; Butler et al. <xref ref-type="bibr" rid="CR13">2023</xref>; Beigel et al. <xref ref-type="bibr" rid="CR7">2020</xref>; Rosas et al. <xref ref-type="bibr" rid="CR104">2021</xref>; Singh et al. <xref ref-type="bibr" rid="CR114">2022</xref>; Cao et al. <xref ref-type="bibr" rid="CR15">2023</xref>). Though several resources are available to the public, the number of cases is still significant due to the many variants that have appeared including Delta and Omicron (Andrews, et al. <xref ref-type="bibr" rid="CR5">2022</xref>; Lopez Bernal, et al. <xref ref-type="bibr" rid="CR72">2021</xref>; Forchette et al. <xref ref-type="bibr" rid="CR32">2021</xref>; Pilz et al. <xref ref-type="bibr" rid="CR94">2022</xref>). Since the end of COVID 19 complications is nowhere in sight it is important to delineate and comprehend the adverse health implications and develop better interventions to treat these diseases. Cytokine storm is one of the various hallmarks for COVID related death (Luo et al. <xref ref-type="bibr" rid="CR75">2020</xref>; Que et al. <xref ref-type="bibr" rid="CR96">2022</xref>; Ragab et al. <xref ref-type="bibr" rid="CR98">2020</xref>; Rincon-Arevalo et al. <xref ref-type="bibr" rid="CR102">2022</xref>; Geng et al. <xref ref-type="bibr" rid="CR33">2021</xref>; Karki, et al. <xref ref-type="bibr" rid="CR49">2021</xref>). Prior to COVID, Jak inhibitors were approved by the FDA for autoimmune conditions such as rheumatoid and psoriatic arthritis (Berteloot, et al. <xref ref-type="bibr" rid="CR10">2021</xref>; Chang and Lai <xref ref-type="bibr" rid="CR18">2019</xref>; Sanachai et al. <xref ref-type="bibr" rid="CR108">2020</xref>; Liang et al. <xref ref-type="bibr" rid="CR69">2020</xref>; Quero et al. <xref ref-type="bibr" rid="CR97">2019</xref>; Long et al. <xref ref-type="bibr" rid="CR71">2022</xref>; Dai, et al. <xref ref-type="bibr" rid="CR23">2021</xref>). Reports suggest the potential of Jak inhibitors and particularly Jak3 inhibitors, in targeting the immune cell thereby reducing the cytokine storm and ameliorating some of the COVID related symptoms (Luo et al. <xref ref-type="bibr" rid="CR75">2020</xref>; Que et al. <xref ref-type="bibr" rid="CR96">2022</xref>; Levy, et al. <xref ref-type="bibr" rid="CR65">2022</xref>; Kramer, et al. <xref ref-type="bibr" rid="CR55">2022</xref>; Sparks et al. <xref ref-type="bibr" rid="CR120">2021</xref>; Kalil et al. <xref ref-type="bibr" rid="CR48">2021</xref>; Marconi et al. <xref ref-type="bibr" rid="CR77">2021</xref>; Murugesan et al. <xref ref-type="bibr" rid="CR89">2022</xref>; Sonkar et al. <xref ref-type="bibr" rid="CR119">2021</xref>; Sarmiento et al. <xref ref-type="bibr" rid="CR109">2021</xref>; Guimaraes et al. <xref ref-type="bibr" rid="CR36">2021</xref>; Maslennikov et al. <xref ref-type="bibr" rid="CR78">2021</xref>). However, Jak3 is also present in other cell-types, importantly in the intestinal mucosal epithelial cells and in the nasopharyngeal mucosal surface which is an important entry point for COVIDs (Kumar et al. <xref ref-type="bibr" rid="CR57">2021</xref>). Reports suggest COVID-19 impacts Jak3 signaling and its inhibition in the immune cells may have potential beneficial effects (Rincon-Arevalo et al. <xref ref-type="bibr" rid="CR102">2022</xref>; Geng et al. <xref ref-type="bibr" rid="CR33">2021</xref>; Karki, et al. <xref ref-type="bibr" rid="CR49">2021</xref>; Li et al. <xref ref-type="bibr" rid="CR67">2021</xref>; Xia et al. <xref ref-type="bibr" rid="CR133">2020</xref>; Zhang, et al. <xref ref-type="bibr" rid="CR139">2022</xref>; Tran et al. <xref ref-type="bibr" rid="CR126">2021</xref>; Feng et al. <xref ref-type="bibr" rid="CR30">2022</xref>). However, information on the role of mucosal Jak3 in COVID prevention and/or treatment is lacking.</p></sec><sec id="Sec18"><title>Jak signaling and the breach of primary barrier during COVID-19</title><p id="Par15">In general, almost all viral infections including COVID-19 have 4 stages that involve viral- entry, replication, assembly, and release. COVID-19 infections require breach of the very first barrier which is the mucosal epithelial cells of both respiratory and gastrointestinal systems. SARS-CoV-2 entry involves attachment of the viruses through spike 1 protein to the alveolar mucosal epithelial cells expressed angiotensin-converting enzyme 2 (ACE2) receptors. The alveolar epithelium secretes mucus, which traps inhaled particles and bacteria and prevents them from reaching the lungs. ACE-2 surface expression is also responsible for viral entry into a variety of other cell types including renal epithelial cells, endothelial cells, cardiac myocytes, and immune cells such as macrophages and monocytes in the spleen and lymph nodes. viral entry to any of these cell types requires breach of the very first barrier which is the mucosal epithelial cells of both respiratory and gastrointestinal systems. The role of JAK signaling in the transcription and activation of ACE2 in lung epithelium has also been reported (Lee et al. <xref ref-type="bibr" rid="CR63">2020</xref>). Reports also suggest (Luo et al. <xref ref-type="bibr" rid="CR74">2021</xref>) a close correlation between ACE2 and JAK-STAT pathway in the regulation of immune responses and a role of overexpressed ACE2 in downstream JAK-STAT signaling to modulate SARS-CoV-2 induced inflammatory responses. Recently, (Al-Ani et al. <xref ref-type="bibr" rid="CR2">2022</xref>) reported the involvement of lung angiotensin II to type 1 receptor (AT1R)-JAK-STAT axis in lipopolysaccharides (LPS)-induced cytokine storm and resulting acute lung injury and coagulopathy corresponding with moderate-to-severe COVID-19 in humans. Similarly, Interferon-alpha 2 is reported to further augment the viral load by upregulating the ACE2 expression in a loop-back mechanism in different cell systems (Wilk et al. <xref ref-type="bibr" rid="CR132">2020</xref>).</p></sec><sec id="Sec19"><title>Jak signaling in COVID-19 escaping natural immunity and viral replication</title><p id="Par16">Jak signaling plays a protective role during viral infection which is indicated by the fact that during the early stages of infection, SARS-CoV-2 induces negative regulator proteins SOCS3 to inhibit JAK2-STAT3 signaling to escape antiviral responses and replicate freely (Zizzo et al. <xref ref-type="bibr" rid="CR145">2022</xref>). In addition, SARS-CoV-2 infection is characterized by the reduced immune cell counts including NK cells, B cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Zheng et al. <xref ref-type="bibr" rid="CR140">2022</xref>) which are not only found in human with Jak3 mutations but also in Jak-KO mice models. Moreover, SARS-CoV-2 virus infected patients show impaired type I interferons mediated antiviral response which are in turn mediated by JAK-STAT pathway (Walz et al. <xref ref-type="bibr" rid="CR130">2021</xref>).</p></sec><sec id="Sec20"><title>Jak signaling in cytokine storm and ARDS symptoms of COVID-19</title><p id="Par17">After viral entry through mucosal breach followed by escaping the natural immunity and viral replications, COVID-19 patients show broad spectrum of clinical symptoms that emanates from significant increase in pro-inflammatory cytokines and chemokines clinically termed as cytokine storm. Among the primary and life threatening symptoms include acute respiratory distress syndrome (ARDS) and multi-organ failure and if uncontrolled, leads to subsequent death (Rarani et al. <xref ref-type="bibr" rid="CR101">2022</xref>). Among the elevated cytokines (IL-2, IL-4, IL-6, IL-7, IL-10, TNF-alpha, IFN-gamma) and chemokines (CCL2, CCL8), see during cytokine storm (Khaledi et al. <xref ref-type="bibr" rid="CR51">2022</xref>) the same JAKs which were initially involved in reinforcing mucosal barrier and natural immunity becomes detrimental and play a key role in immunopathology of COVID-19 disease through increased cytokine production via IL-6/GM-CSF/JAK-STAT axis. In addition, these Jak-signaling also facilitate recruitment of macrophages, monocytes, neutrophils, natural killer cells, lymphocytes, and dendritic cells augmenting cytokine production leading to ARDS and even death. Among the examples of individual Jaks involved include JAK1,2 mediated localized complement hyperactivation (Yan, et al. <xref ref-type="bibr" rid="CR134">2021</xref>). IL-2 induced JAK1,3 mediated cytotoxicity of NK cells, and IL-6 induced JAK1 mediated IL-15 production and NK cell development, growth, and functioning (Gotthardt et al. <xref ref-type="bibr" rid="CR35">2019</xref>). Another key growth factor TGF&#x003b2; that stimulate pulmonary fibrosis during COVID-19 acute lung injury are produced due to JAK1-STAT1 dysregulation led hyperactivation of STAT3 which is a key transcription factor for the overexpression of harmful IL-6 that stimulates transforming growth factor-1beta (Matsuyama et al. <xref ref-type="bibr" rid="CR79">2020</xref>) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Model for Jak3-mediated normal lung physiology and its implications during COVID-19 infections mediated compromised lung functions. <bold>A</bold>&#x000a0;Under normal physiological conditions, Jak-3 activation facilitated the surface expression of ACE2 that maintains lung epithelial homeostasis and vasodilation-mediated normal lung functions through Ang 1&#x02013;7 formation and its interactions with its receptor MAS/G. <bold>B</bold> SARS COVID-19 infection through its entry into lung mucosal epithelial lining through ACE2 however leads to loss of ACE2, accumulation of Ang-II, activation of AT1 and AT2 by Ang-II, and mucosal epithelial cell death, fibrosis, vasoconstriction, hypertension, and coagulopathy-associated health complications</p></caption><graphic xlink:href="10020_2025_1260_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec21"><title>Current state of Jak inhibitor drugs</title><p id="Par18">Though the crystal structure of the kinase domain for all JAKs has been determined in the active state conformation, the three-dimensional structure of full length JAKs is still unclear. For that reason, currently available all Jak inhibitors (Jakinibs) are screened against only the truncated kinase domain while human body expresses full length Jaks where other domains of Jaks influence the binding of not only Jak substrates but also its own activation through binding of ATP. Interestingly, a patent exists for screening Jak3 inhibitors using full-length Jak3 (US patent# US 9,739,779). Moreover, the Jak inhibitors are usually categorized as first- or second- generation Jakinibs. The first-generation Jakinibs works through competitive inhibition of ATP binding site on the JH1 kinase domain. Since the ATP-binding site is highly conserved among JAKs, the first-generation Jakinibs targeted multiple Jak member both in vitro and in vivo (Ferrao and Lupardus <xref ref-type="bibr" rid="CR31">2017</xref>). These resulted in the inhibition of multiples pathways regulated by different Jaks in several tissues resulting in off-target binding of the currently available drugs/inhibitors and consequent adverse effects (Clark et al. <xref ref-type="bibr" rid="CR21">2014</xref>). Subsequent efforts were made to develop next-generation Jakinibs to increase the specificity and selectivity to JAKs which were still targeted to the ATP-binding site through non-covalent competitively and non-covalent binding though some also targeted the JH2 pseudo-kinase domain of JAK (Deucravacitinib) while other inhibited the same truncated domain of JAKs through covalent binding (Ritlecitinib) (Casimiro-Garcia et al. <xref ref-type="bibr" rid="CR16">2018</xref>; Burke, et al. <xref ref-type="bibr" rid="CR12">2019</xref>). Since the binding site and the mode of screening largely remains unchanged and conserved across several Jaks, it is unlikely that the specificity and the adverse events would improve significantly (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Jak3 and Covid in Epithelial and immune cells. Model for the central roles of Jak3 in respiratory epithelial cells (REC) and immune cells and its implication during SARS COVID-19 infection. While in REC, Jak3 suppresses COVID-mediated TLR activation and reduced cytokine production, and these are compromised due to reduced Jak3 expression led increased cytokine production through NF-kB in patients with obesity, diabetes, and metabolic syndrome. These cytokines in turn further activate the circulating immune cells causing cascade effects of cytokine syndrome. Therefore, Jak3 targeted drugs have limited efficacies due to suppression of Jaks in both REC and immune cells where though it impacts the cytokine syndrome, however, compromises lung functions due to loss of protective effects by REC</p></caption><graphic xlink:href="10020_2025_1260_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec22"><title>Structure of Jak1, jak2, Jak3 and Tyk2 proteins and their interactions with specific inhibitors</title><p id="Par19">Understanding the structural domains of Jaks and their roles in its activation and inhibition is crucial for the rational design of selective inhibitors. The kinase domain of JAK1 contains an ATP-binding site that is a primary target for small-molecule inhibitors designed to modulate JAK1 activity. High-resolution crystal structures have revealed that inhibitors bind deep within this ATP-binding pocket, interacting with key residues such as Glu957 and Leu959 in the hinge region. These interactions are specific and crucial for the potency and selectivity of the inhibitors (Raivola et al. <xref ref-type="bibr" rid="CR99">2019</xref>). By targeting specific residues within the ATP-binding site, it is possible to develop compounds that effectively modulate JAK1 activity with reduced off-target effects, enhancing therapeutic efficacy in treating diseases involving dysregulated JAK-STAT signaling.&#x0200b; Baricitinib (JAK1/2) and ruxolitinib (JAK1/2) have been used in severe COVID-19 to dampen hyperinflammation (Hasselbalch et al. <xref ref-type="bibr" rid="CR42">2021</xref>; Vannucchi, et al. <xref ref-type="bibr" rid="CR129">2021</xref>). pure JAK1 inhibitors like Upadacitinib haven&#x02019;t seen widespread COVID-19 use, the therapeutic potential of this drug against Covid needs to be investigated (Sonkar et al. <xref ref-type="bibr" rid="CR119">2021</xref>).</p><p id="Par20">The kinase domain of JAK2 contains an ATP-binding site that is the primary target for small-molecule inhibitors designed to modulate JAK2 activity. These inhibitors can be categorized based on their binding modes.&#x0200b; Type I Inhibitors bind to the active conformation of the kinase domain, occupying the ATP-binding site (Ruxolitinib and fedratinib) which are used clinically to treat myeloproliferative disorders (Vannucchi, et al. <xref ref-type="bibr" rid="CR129">2021</xref>; Tefferi et al. <xref ref-type="bibr" rid="CR124">2023</xref>; Keenan et al. <xref ref-type="bibr" rid="CR50">2024</xref>; Naik et al. <xref ref-type="bibr" rid="CR90">2022</xref>). Type II Inhibitors target the inactive conformation (DFG-out) of the kinase domain, binding to the ATP-binding site and an adjacent hydrophobic pocket.&#x0200b; (NVP-BBT594 and NVP-CHZ868) which exhibit selective inhibition of JAK2 (Keenan et al. <xref ref-type="bibr" rid="CR50">2024</xref>). Additionally, allosteric inhibitors that bind to sites remote from the active site are being explored to achieve greater specificity and reduce off-target effects. These inhibitors offer a potential advantage by modulating JAK2 activity without directly competing with ATP binding (Liang et al. <xref ref-type="bibr" rid="CR70">2023</xref>).</p><p id="Par21">The structural organization of TYK2 provides multiple targets for small-molecule inhibitors such as ATP-Competitive Inhibitors bind to the ATP-binding site within the kinase domain (JH1), directly competing with ATP and inhibiting kinase activity (Ropsacitinib and Brepocitinib) which target the catalytic ATP-binding sites, have shown efficacy in modulating TYK2 activity (Kimball, et al. <xref ref-type="bibr" rid="CR52">2024</xref>; Zhou et al. <xref ref-type="bibr" rid="CR142">2022</xref>). Allosteric Inhibitors bind to the pseudokinase domain (JH2), inducing conformational changes that stabilize the autoinhibited state of TYK2, thereby preventing activation.&#x0200b; Targeting the pseudokinase domain offers a novel approach to achieve specificity, as demonstrated by the development of allosteric inhibitors like deucravacitini. Deucravacitinib is a selective TYK2 inhibitor that binds allosterically to the JH2 domain, preventing receptor-mediated activation. &#x0200b; These inhibitors provide therapeutic potential with improved selectivity and reduced off-target effects compared to traditional ATP-competitive inhibitors (Lebwohl et al. <xref ref-type="bibr" rid="CR62">2024</xref>). In summary, the detailed structural organization of TYK2, particularly its pseudokinase and kinase domains, provides a foundation for developing targeted therapies aimed at modulating TYK2-mediated signaling pathway.</p></sec><sec id="Sec23"><title>Implications for drug resistance and therapeutic innovation</title><p id="Par22">Structural changes, e.g., point mutations arising within the kinase or pseudo kinase domains, may confer resistance to JAK inhibitors. For example, mutations JAK1 Y1034 C or JAK3 L857Q prevent drug binding but retain kinase activity (Koppikar et al. <xref ref-type="bibr" rid="CR53">2012</xref>). Comprehension of the three-dimensional structure and conformational dynamics of JAK domains is therefore necessary for the control of resistance mechanisms and next-generation inhibitor design. Advances in cryo-electron microscopy and X-ray crystallography have illuminated the full-length architecture of JAKs in complex with receptors and inhibitors, illuminating inter-domain communication and allosteric sites accessible to therapeutic intervention (Glassman et al. <xref ref-type="bibr" rid="CR34">2022</xref>). Resistance to JAK inhibitors can be caused by point mutations in the pseudo kinase domain or ATP-binding site. These mutations can disrupt drug binding but preserve kinase activity. For instance, mutations such as JAK1 Y1034 C and JAK2 R683S have been shown to decrease sensitivity to inhibitors (Downes et al. <xref ref-type="bibr" rid="CR27">2021</xref>).</p></sec><sec id="Sec24"><title>Therapeutic combinations of JAK inhibitors and other Covid drug</title><p id="Par23">Monotherapy is not always the best option, however, and combination therapy regimens with other anti-inflammatory drugs are used to optimize clinical responses or reduce corticosteroid therapy. The therapeutic basis for combination of JAK inhibitors with drugs like corticosteroids, methotrexate (MTX), or biologics is their complementary mechanism of action and synergistic immunosuppressive potential. To improve the clinical outcomes such as oxygenation and survival in moderate to severe cases of Covid, Corticosteroids (like dexamethasone) is used in combination with JAK inhibitors to reduce systemic inflammation associated with the cytokine storm (Meyer et al. <xref ref-type="bibr" rid="CR82">2020</xref>). However, there is a risk for additive immunosuppression and secondary infections. Corticosteroids have broad anti-inflammatory actions through the inhibition of pro-inflammatory gene transcription and inhibition of varied immune cell functions. Combination with JAK inhibitors, which block cytokine receptor-mediated JAK-STAT signaling, can result in synergistic inhibition of inflammatory mediators. For instance, combination therapy with baricitinib and dexamethasone in COVID-19-associated cytokine storm led to a significant reduction in mortality. The COV-BARRIER trial demonstrated that the addition of baricitinib to standard of care (including corticosteroids) reduced 28-day mortality by 38.2% compared to placebo (Marconi et al. <xref ref-type="bibr" rid="CR77">2021</xref>). Compared to Remdesivir alone, Baricitinib and Remdesivir along with corticosteroids showed quicker recovery and less progression to ventilation in the COVID-19 (ACTT-2 Trial) (So et al. <xref ref-type="bibr" rid="CR117">2021</xref>). Subgroup studies revealed greater advantages in those already taking corticosteroids to facilitate faster recovery and better clinical improvement than remdesivir alone antivirals are used in combination with the JAK inhibitors (JAK Inhibitors +&#x02009;Antivirals (e.g., Remdesivir (in ACTT-2 trial) to limit viral replication To combat the cytokine storm,.(JAK Inhibitors +&#x02009;IL-6 Inhibitors (e.g., Tocilizumab): both drugs are used, and both affect IL-6 signaling but through different mechanisms (Portsmore et al. <xref ref-type="bibr" rid="CR95">2020</xref>). Overlapping effects might not offer additive benefits and could increase infection risk. For that reason, clinical trials usually prefer one or the other, not both. JAK Inhibitors and Biologics: Although theoretically appealing, the combination of JAK inhibitors with biologic DMARDs, including anti-TNF or anti-IL-6 therapy, is usually avoided because of safety issues, especially opportunistic infections, and thromboembolic events. The majority of clinical trials exclude patients on the two therapies simultaneously, and regulatory recommendations are that these combinations are not to be employed. Off-label use in the context of refractory disease has been described in case series, and additional controlled studies are required to confirm safety and efficacy.</p></sec><sec id="Sec25"><title>Limitations of current Jak inhibitor drugs and possible alternate strategies to overcome them</title><p id="Par24">Though Jak inhibitor drugs provide several advantages such as multi-target blocking and ease of administration over biologics, there are serious concerns related to the management and treatment of serious adverse effects such as gastrointestinal events, ulcerative colitis, serious infections, thrombotic complications, cardiovascular disorders, malignant tumors, and major risks of deaths, which are more significant than the use of biologics (Tanaka et al. <xref ref-type="bibr" rid="CR122">2022</xref>). The molecular basis of some of these includes overexpressed JAK3 downstream to MAPK signaling is reported to mediate platelet hyperactivation. Hence, neither Pan-Jak inhibitor nor JAK1-2 inhibitors are potent therapeutic options. Albeit clinical trials using Jak3 specific inhibitors are needed. In addition, data suggest use of irreversible Jak inhibitors is potentially dangerous due to the risk of severe immunodeficiency. Therefore, temporary use of competitive Jak inhibitors may provide relatively safer and efficacious alternative for treating the chronic inflammatory pathology including COVID-19 (Rommasi et al. <xref ref-type="bibr" rid="CR103">2022</xref>). Moreover, since JAK2 appears to be not involved in type I or type II interferon-signaling, selective Jak-2 specific inhibitors may provide a better outcome for suppressing IL-6-GM-CSF-signaling-in COVID-19-associated cytokine storms. Likewise, Jak inhibitors treatment also cause significant reduction in humoral immunity following vaccination against SARS-CoV-2 in rheumatoid arthritis patients. Therefore, future trails involving stratification of patients based of the stages of severity using blood cytokines to determine precise timing of the treatment may provide a better outcome. Since Jak inhibitors are an attractive alternate in combination with adjuvant therapy, more results are needed to establish the safety and efficacy particularly using suitable combination modalities under clinical setting. Moreover, the majority of results are based on relatively small sample size lacking head-to-head clinical trial comparisons. Therefore, data must be accumulated to establish drug safety with risk-free utilization of these inhibitors by specialists who can identify the potential patient cohorts who might benefit from these inhibitors the most. Though up to 2021, the FDA and EMA authorized seven Jak inhibitors for the treatment of various therapeutic conditions, in 2022 only, three new Jak inhibitors got approval from FDA for the first time, expanding the Jak inhibitor portfolio to a total of 10 approved Jak inhibitors for human and veterinary use, in United states. Since the discovery of Jaks over 40 years ago, the last three decades have witnessed Jak directed drug development undergo drastic translation from bench to bedside where they have become an integral part of therapeutic options for heterogenous group of ailments either as an alternative treatment for the conditions in which other biologics failed or as the sole mainstay treatment of conditions without prior approved therapeutic agents. The current hope is that with the use of better strategies these and many more Jak inhibitors will be able to address the unmet clinical needs of many more autoimmune and chronic inflammatory conditions including COVID-19.</p></sec><sec id="Sec26"><title>Prospective on oral <italic>vs</italic> trans mucosal delivery routes to administer Jak3 targeted drugs</title><p id="Par25">Though a receptor for SARS-CoV-2, under physiological conditions, ACE2 protects against lung injury by: (a) degrading Ang II, which is vasoconstrictive and proapoptotic for lung epithelial cells and profibrotic, and (b) by producing the peptide Ang1-7, which inhibits the actions of Ang II through binding to the MAS receptor. In support of this protective role for ACE2, pharmaceutical preparations of recombinant ACE2, when administered to experimental animals, protect against lung cell death, inhibit acute lung injury and prevent lung fibrosis after chronic injury to the lungs (Samavati and Uhal <xref ref-type="bibr" rid="CR107">2020</xref>). In addition, MUC4 mucin, a ligand activates ErbB2, a receptor tyrosine kinase that modulates Airway Epithelial Cells (AEC) proliferation following damage in airways of asthmatic patients. The activation of Jak3 has been reported to upregulate the expression of both ACE2 and MUC4 in AEC (Lee et al. <xref ref-type="bibr" rid="CR64">2021</xref>; Damera et al. <xref ref-type="bibr" rid="CR24">2006</xref>). Jaks in general and Jak3 are widely expressed in both immune cells and intestinal epithelial cells (IECs) of both humans and mice. Structural implications of Jak3 domains beyond the immune cells and in gastrointestinal functions suggest that Jak functions are important for gastrointestinal wound repair and protection from predisposition to inflammatory bowel disease, obesity-associated metabolic syndrome, and epithelial cancers. In light of these, it is not surprising that Jak and Jak3 inhibitor treatment during COVID-19 leads to adverse effects including respiratory tract infection, gastrointestinal events, and ulcerative colitis (Table <xref rid="Tab1" ref-type="table">1</xref>) and which appears to be because of interference with the protective roles of mucosal epithelial functions of these Jaks in airways and gastrointestinal tracts (Kumar et al. <xref ref-type="bibr" rid="CR57">2021</xref>). These suggest that Jaks have both beneficial functions through its actions in mucosal epithelial cells and detrimental functions during COVID-19 infections associated cytokine storm through uncontrolled activation of immune cells. Therefore, targeting immune cell functions during this infection may mitigate the adverse impacts and provide a better outcome through transmucosal drug administration as an alternative route.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Completed, terminated, or undergoing clinical trials of some of the JAK inhibitors available around the world. JAK inhibitors are known for their severe adverse events (AE), such as respiratory failure, cardiac failure, venous thromboembolism, and severe infections, such as septic shock, pneumonia, herpes zoster-related diseases, malignancies, and more. Although some of these clinical trials were completed, only a few are currently approved in the United States for consumer use. Other products are either available in other countries, have been discontinued since it was found non-significant in their studies, or are in the process of determining safety and efficacy, like CPL409116. (References in the table are provided separately in the Supplemental material section)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ClinicalTrials.gov Identifier and Status</th><th align="left">Drug</th><th align="left">Route</th><th align="left">Target</th><th align="left">Primary Outcome</th><th align="left">Phase</th><th align="left">Adjuvant Therapy</th><th align="left">Limitations/AE's</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">NCT03758443, Terminated</td><td align="left">Izencitinib</td><td align="left">Oral</td><td align="left">Pan-JAK</td><td align="left">1. Change from baseline in Total Mayo Score (tMS) at 8 weeks. 2. Phase 3 Maintenance: Number of participants who demonstrated clinical remission by adapted Mayo Score components at maintenance week (mWeek) 44.</td><td align="left">Phase 3</td><td align="left">N/A</td><td align="left">The study was terminated early by company decision due to interim analysis results. Serious AEs: Colitis ulcerative.</td><td align="left">(Alam et al. <xref ref-type="bibr" rid="CR1">2021</xref>)</td></tr><tr><td align="left">NCT03732807, Completed</td><td align="left">Ritlecitinib</td><td align="left">Oral</td><td align="left">JAK3/TEC</td><td align="left">Percentage of participants with an absolute severity of alopecia tool (SALT) score of less than or equal to 20 at week 24 (time frame: week 24].</td><td align="left">Phase 3</td><td align="left">N/A</td><td align="left">AEs: upper respiratory tract infection. Serious AEs: herpes zoster, serious infections.</td><td align="left">(Parvathaneni and Gupta <xref ref-type="bibr" rid="CR91">2020</xref>)</td></tr><tr><td align="left">NCT04401579, Completed</td><td align="left">Baricitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2</td><td align="left">Overall time to recovery from COVID-19, and time to recovery based on race, ethnicity, and sex.</td><td align="left">Phase 3</td><td align="left">Remdesivir</td><td align="left">Serious AEs: respiratory failure</td><td align="left">(Bellera et al. <xref ref-type="bibr" rid="CR8">2021</xref>)</td></tr><tr><td align="left">NCT04404361, Terminated</td><td align="left">Pacritinib</td><td align="left">Oral</td><td align="left">JAK2/IRAK1</td><td align="left">Proportion of patients, infected with COVID-19, who progress to IMV and/or ECMO or death during the 28 days following randomization</td><td align="left">Phase 3</td><td align="left">Standard of Care</td><td align="left">Serious AEs: cardiac events, bleeding, gastrointestinal events, infections (septic shock, pneumonia).</td><td align="left">(Indari et al. <xref ref-type="bibr" rid="CR44">2021</xref>)</td></tr><tr><td align="left">NCT04366232, Terminated</td><td align="left">Ruxolitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2</td><td align="left">At least 3 parameters in the biological criteria are met, including CRP and/or Ferritin among: (a) CRP: decrease &#x0003e; 50%, (b) Ferritinemia: decrease &#x0003e; 1/3, (c) Serum creatine: decrease &#x0003e; 1/3, (d) AST/ALT: decrease &#x0003e; 50%, (e) Eosinophils &#x0003e;50/mm3, (f) Lymphocytes &#x0003e; 1000/mm3</td><td align="left">Phase 2</td><td align="left">Standard of Care, Anakinra</td><td align="left">The study was terminated by the investigator.</td><td align="left">(Chakraborty et al. <xref ref-type="bibr" rid="CR17">2021</xref>)</td></tr><tr><td align="left">NCT04359290, Completed</td><td align="left">Ruxolitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2</td><td align="left">Overall survival in subjects with severe COVID-19</td><td align="left">Phase 2</td><td align="left">Dexamethasone</td><td align="left">Severe AEs: Life threatening pneumonia</td><td align="left">(Branco et al. <xref ref-type="bibr" rid="CR11">2020</xref>)</td></tr><tr><td align="left">NCT04377620, Completed</td><td align="left">Ruxolitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2</td><td align="left">Percentage of Participants Who Have Died Due to Any Cause</td><td align="left">Phase 3</td><td align="left">Standard of Care</td><td align="left">Severe AEs: Abnormal laboratory parameters, renal/urinary disorders, respiratory disorders, vascular disorders.</td><td align="left">(Shanker et al. <xref ref-type="bibr" rid="CR111">2024</xref>)</td></tr><tr><td align="left">NCT04334044, Completed</td><td align="left">Ruxolitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2</td><td align="left">Recover of pneumonia characterized by cease of respiratory symptoms.</td><td align="left">Phase 1 &#x00026; 2</td><td align="left">N/A</td><td align="left">Severe AEs: abnormal laboratory parameters, hypertension, acute kidney injury, vascular device infection.</td><td align="left">(Shanker et al. <xref ref-type="bibr" rid="CR111">2024</xref>)</td></tr><tr><td align="left">NCT04402866, Completed</td><td align="left">Nezulcitinib (TD-0903)</td><td align="left">Oral Inhalation</td><td align="left">Pan-JAK</td><td align="left">Number of respiratory failure-free days from randomization to day 28.</td><td align="left">Phase 2</td><td align="left">Standard of Care, Corticosteroids, Heparin, Remdesivir</td><td align="left">Severe AEs: acute respiratory failure, ventricular fibrillation, fatal MODS, and ischemic stroke.</td><td align="left">(Satarker et al. <xref ref-type="bibr" rid="CR110">2021</xref>; Amini-Farsani et al. <xref ref-type="bibr" rid="CR4">2021</xref>)</td></tr><tr><td align="left">NCT03281304, Terminated</td><td align="left">Tofacitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2/JAK3</td><td align="left">Number of participants, diagnosed with ulcerative colitis, with remission based on modified mayo score at month 6.</td><td align="left">Phase 4</td><td align="left">N/A</td><td align="left">Severe AEs: herpes zoster, infections.</td><td align="left">(McGee et al. <xref ref-type="bibr" rid="CR80">2021</xref>)</td></tr><tr><td align="left">NCT02535689, Completed</td><td align="left">Tofacitinib</td><td align="left">Oral</td><td align="left">JAK1/JAK2/JAK3</td><td align="left">Safety of tofacitinib in systemic lupus erythematosus (SLE) patients.</td><td align="left">Phase 1</td><td align="left">Some eligible patients were on prednisone during the treatment period.</td><td align="left">Severe AEs: Cardiac disorders, gastrointestinal disorders, infections, nervous system disorders.</td><td align="left">(Zheng et al. <xref ref-type="bibr" rid="CR141">2021</xref>)</td></tr><tr><td align="left">NCT02308163, Completed</td><td align="left">Peficitinib</td><td align="left">Oral</td><td align="left">Pan-JAK</td><td align="left">Percentage of Participants with an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</td><td align="left">Phase 3</td><td align="left">N/A</td><td align="left">Severe AEs: serious infections, herpes zoster-related disease, malignances.</td><td align="left">(Spinelli et al. <xref ref-type="bibr" rid="CR121">2020</xref>)</td></tr><tr><td align="left">NCT01590459, Completed</td><td align="left">Decernotinib</td><td align="left">Oral</td><td align="left">JAK3</td><td align="left">Proportion of subjects who achieve a 20% improvement in disease severity according to the American College of Rheumatology criteria, assessed using the C-reactive protein level (ACR20-CRP) response, within twelve weeks.</td><td align="left">Phase 2</td><td align="left">Methotrexate</td><td align="left">AEs: headaches, elevated levels of transaminases, lipoproteins, creatine, LDL and HDL cholesterol.</td><td align="left">(Cantini et al. <xref ref-type="bibr" rid="CR14">2020</xref>)</td></tr><tr><td align="left">NCT04670757, Completed</td><td align="left">CPL409116</td><td align="left">Oral</td><td align="left">JAK1/JAK3/Pan-ROCK</td><td align="left">(1) Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP, (2) Safety and tolerability of IMP after single and multiple oral administration</td><td align="left">Phase 1</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">(Roschewski, et al.&#x000a0;<xref ref-type="bibr" rid="CR105">2020</xref>; Jacobs et al. <xref ref-type="bibr" rid="CR45">2021</xref>)</td></tr><tr><td align="left">NCT05374785, Recruiting</td><td align="left">CPL409116</td><td align="left">Oral</td><td align="left">JAK1/JAK3/Pan-ROCK</td><td align="left">Change in Disease Activity Score 28 joint count C reactive protein (DAS28(CRP)).</td><td align="left">Phase 2</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">(Roschewski, et al.&#x000a0;<xref ref-type="bibr" rid="CR105">2020</xref>; Jacobs et al. <xref ref-type="bibr" rid="CR45">2021</xref>)</td></tr><tr><td align="left">NCT03728023, Completed</td><td align="left">Golidocitinib (AZD4205)</td><td align="left">Oral</td><td align="left">JAK1</td><td align="left">The number of healthy subjects with adverse events, abnormal laboratory parameters, abnormal vital signs, and abnormal electrocardiogram</td><td align="left">Phase 1</td><td align="left">N/A</td><td align="left">AEs: Abnormal laboratory parameters (neutropenia, leukopenia, increased ALT, AST, and LDL), gastrointestinal and respiratory disorders.</td><td align="left">(Basile et al. <xref ref-type="bibr" rid="CR6">2022</xref>; Roy et al. <xref ref-type="bibr" rid="CR106">2021</xref>)</td></tr><tr><td align="left">NCT03450330, Completed</td><td align="left">Golidocitinib (AZD4205)</td><td align="left">Oral</td><td align="left">JAK1</td><td align="left">Safety and tolerability of AZD4205 in subjects with nonsmall cell lung cancer.</td><td align="left">Phase 1 &#x00026; 2</td><td align="left">Osimertinib</td><td align="left">AEs: Abnormal laboratory parameters (neutropenia, leukopenia, increased ALT, AST, and LDL), gastrointestinal and respiratory disorders.</td><td align="left">(Basile et al. <xref ref-type="bibr" rid="CR6">2022</xref>; Roy et al. <xref ref-type="bibr" rid="CR106">2021</xref>)</td></tr></tbody></table></table-wrap></p><p id="Par26">With significant number of Jak inhibitors under clinical trials this combined with continued sustenance of COVID-19 pandemic deserves a need for alternative routes of administration of Jak inhibitor drugs for end of life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual, and rectal. In addition to being non-invasive routes for systemic drug delivery, it also provides the possibility of self-administration, or administration by family caregivers not to mention their ability to offer rapid onset of action with reduced first-pass metabolism making them suitable for use in palliative and end-of life care to provide fast relief of symptoms. This is particularly important in COVID-19, as patients can deteriorate rapidly. However, these alternate routes also come with challenges including a relatively small surface area for effective drug absorption, small volume of fluid for drug dissolution and the presence of a mucus barrier, that may limit the number of drugs that that may qualify for suitability for delivery through the transmucosal route (Lam et al. <xref ref-type="bibr" rid="CR60">2020</xref>).</p></sec></sec><sec id="Sec27"><title>Concluding remarks</title><p id="Par27">Janus Kinase 3 is a non-receptor tyrosine kinase belonging to the Jak family that is highly expressed in immune cells. Accumulating evidence including our research indicates that they are also expressed in a variety of non-immune cells tissues such as intestinal and lung epithelial cells (or mucosal jak3) and brain cells, liver cells. Mucosal jak3 are adjacent to the immune cells and immune cell Jak3 which is the reason behind the cytokine storm. So immune cell Jak3 is a potential target for covid treatment. Here we discuss the challenges and strategies to target these immune cell Jak3 with the Jak3 targeted drugs. As the understanding of the mucosal Jak3 and their intestinal tissue specific functions continue to improve, mucosal Jak3 and its role in maintaining the mucosal and immune cross talk will be identified. In that way the use of other formulation of Jak3 other than oral directed drugs will be explored to target immune cell Jak3. Immune cell Jak3 generally over activated in the covid patients leading to cytokine storm, which would allow the development of drugs acting at selective sites only. Advances in the basic knowledge of mucosal Jak3, their intestinal tissue specific functions, aboral formulation of Jak3 -directed drugs, and delivery systems will aid in the development of new therapeutic strategies targeting these immune cell Jak3 in combating covid while protecting the mucosal Jak3.</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10020_2025_1260_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JM and NK conceptualized the ideas, wrote the original draft text, reviewed and edited the final manuscript. DS, PK, and SK prepared the table and figures for the original draft, HA, PK and SK provided intellectual contribution in writing individual subsections, and reviewed and edited the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by Discovery Foundation, Advancing the Discovery to Market and High impact seedling grant to JM and NK.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par28">The content in the manuscript does not require since no human or animal subjects were used for the information contained in this manuscript.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par29">All the accompanying images or data in this manuscript are original and do not require the third-party consent to publish.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>659577</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.659577</pub-id><pub-id pub-id-type="pmid">34220503</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Alam S, et al. Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021. Front Pharmacol. 2021;12:659577.<pub-id pub-id-type="pmid">34220503</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ani</surname><given-names>B</given-names></name><etal/></person-group><article-title>Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat model that mimics moderate and severe Covid-19 pathology</article-title><source>Clin Exp Pharmacol Physiol</source><year>2022</year><volume>49</volume><issue>4</issue><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.13620</pub-id><pub-id pub-id-type="pmid">35066912</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Al-Ani B, et al. Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat model that mimics moderate and severe Covid-19 pathology. Clin Exp Pharmacol Physiol. 2022;49(4):483&#x02013;91.<pub-id pub-id-type="pmid">35066912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Kamjani</surname><given-names>MH</given-names></name><name><surname>Kesselman</surname><given-names>MM</given-names></name></person-group><article-title>The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19</article-title><source>Recent Pat Antiinfect Drug Discov</source><year>2020</year><volume>15</volume><issue>2</issue><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.2174/1574891X15666200922155712</pub-id><pub-id pub-id-type="pmid">32962623</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ali A, Kamjani MH, Kesselman MM. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19. Recent Pat Antiinfect Drug Discov. 2020;15(2):104&#x02013;12.<pub-id pub-id-type="pmid">32962623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Amini-Farsani</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>100</volume><fpage>108071</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2021.108071</pub-id><pub-id pub-id-type="pmid">34482267</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Amini-Farsani Z, et al. Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways. Int Immunopharmacol. 2021;100:108071.<pub-id pub-id-type="pmid">34482267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>N</given-names></name><etal/></person-group><article-title>Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>16</issue><fpage>1532</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2119451</pub-id><pub-id pub-id-type="pmid">35249272</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Andrews N, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532&#x02013;46.<pub-id pub-id-type="pmid">35249272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>MS</given-names></name><etal/></person-group><article-title>The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19</article-title><source>Drug Discov Today</source><year>2022</year><volume>27</volume><issue>3</issue><fpage>848</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2021.11.002</pub-id><pub-id pub-id-type="pmid">34763066</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Basile MS, et al. The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19. Drug Discov Today. 2022;27(3):848&#x02013;56.<pub-id pub-id-type="pmid">34763066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Remdesivir for the Treatment of Covid-19 - Final Report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>19</issue><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmid">32445440</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Beigel JH, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813&#x02013;26.<pub-id pub-id-type="pmid">32445440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Bellera</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Can drug repurposing strategies be the solution to the COVID-19 crisis?</article-title><source>Expert Opin Drug Discov</source><year>2021</year><volume>16</volume><issue>6</issue><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1080/17460441.2021.1863943</pub-id><pub-id pub-id-type="pmid">33345645</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Bellera CL, et al. Can drug repurposing strategies be the solution to the COVID-19 crisis? Expert Opin Drug Discov. 2021;16(6):605&#x02013;12.<pub-id pub-id-type="pmid">33345645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Benmansour</surname><given-names>R</given-names></name><etal/></person-group><article-title>TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco</article-title><source>Int J Immunopathol Pharmacol</source><year>2024</year><volume>38</volume><fpage>3946320241257241</fpage><pub-id pub-id-type="doi">10.1177/03946320241257241</pub-id><pub-id pub-id-type="pmid">38760017</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Benmansour R, et al. TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco. Int J Immunopathol Pharmacol. 2024;38:3946320241257241.<pub-id pub-id-type="pmid">38760017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><mixed-citation publication-type="other">Berteloot L, et al. Alternative pathways for the development of lymphoid structures in humans. Proc Natl Acad Sci U S A. 2021;118(29). 10.1073/pnas.2108082118.</mixed-citation></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Branco</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>MN</given-names></name><name><surname>Alberca</surname><given-names>RW</given-names></name></person-group><article-title>The Possible dual role of the ACE2 receptor in asthma and coronavirus (SARS-CoV2) Infection</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>550571</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.550571</pub-id><pub-id pub-id-type="pmid">33072624</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Branco A, Sato MN, Alberca RW. The Possible dual role of the ACE2 receptor in asthma and coronavirus (SARS-CoV2) Infection. Front Cell Infect Microbiol. 2020;10:550571.<pub-id pub-id-type="pmid">33072624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain</article-title><source>Sci Transl Med</source><year>2019</year><volume>11</volume><issue>502</issue><fpage>eaaw1736</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw1736</pub-id><pub-id pub-id-type="pmid">31341059</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Burke JR, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.<pub-id pub-id-type="pmid">31341059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial</article-title><source>Lancet</source><year>2023</year><volume>401</volume><issue>10373</issue><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)02597-1</pub-id><pub-id pub-id-type="pmid">36566761</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Butler CC, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281&#x02013;93.<pub-id pub-id-type="pmid">36566761</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Cantini</surname><given-names>F</given-names></name><etal/></person-group><article-title>Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</article-title><source>J Infect</source><year>2020</year><volume>81</volume><issue>2</issue><fpage>318</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.017</pub-id><pub-id pub-id-type="pmid">32333918</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cantini F, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318&#x02013;56.<pub-id pub-id-type="pmid">32333918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><issue>5</issue><fpage>406</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2208822</pub-id><pub-id pub-id-type="pmid">36577095</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cao Z, et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19. N Engl J Med. 2023;388(5):406&#x02013;17.<pub-id pub-id-type="pmid">36577095</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Casimiro-Garcia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors</article-title><source>J Med Chem</source><year>2018</year><volume>61</volume><issue>23</issue><fpage>10665</fpage><lpage>10699</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01308</pub-id><pub-id pub-id-type="pmid">30423248</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Casimiro-Garcia A, et al. Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors. J Med Chem. 2018;61(23):10665&#x02013;99.<pub-id pub-id-type="pmid">30423248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>C</given-names></name><etal/></person-group><article-title>The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>704205</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.704205</pub-id><pub-id pub-id-type="pmid">34867318</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Chakraborty C, et al. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol. 2021;12:704205.<pub-id pub-id-type="pmid">34867318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Lai</surname><given-names>AG</given-names></name></person-group><article-title>An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components</article-title><source>Mol Med</source><year>2019</year><volume>25</volume><issue>1</issue><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s10020-019-0114-1</pub-id><pub-id pub-id-type="pmid">31684858</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Chang WH, Lai AG. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components. Mol Med. 2019;25(1):46.<pub-id pub-id-type="pmid">31684858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiodini</surname><given-names>P</given-names></name><etal/></person-group><article-title>A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan</article-title><source>Contemp Clin Trials Commun</source><year>2020</year><volume>20</volume><fpage>100665</fpage><pub-id pub-id-type="doi">10.1016/j.conctc.2020.100665</pub-id><pub-id pub-id-type="pmid">33043164</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chiodini P, et al. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan. Contemp Clin Trials Commun. 2020;20:100665.<pub-id pub-id-type="pmid">33043164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study</article-title><source>BMJ</source><year>2021</year><volume>374</volume><fpage>n1943</fpage><pub-id pub-id-type="doi">10.1136/bmj.n1943</pub-id><pub-id pub-id-type="pmid">34417165</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chung H, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:n1943.<pub-id pub-id-type="pmid">34417165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>JD</given-names></name><name><surname>Flanagan</surname><given-names>ME</given-names></name><name><surname>Telliez</surname><given-names>J-B</given-names></name></person-group><article-title>Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: Miniperspective</article-title><source>J Med Chem</source><year>2014</year><volume>57</volume><issue>12</issue><fpage>5023</fpage><lpage>5038</lpage><pub-id pub-id-type="doi">10.1021/jm401490p</pub-id><pub-id pub-id-type="pmid">24417533</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Clark JD, Flanagan ME, Telliez J-B. Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: Miniperspective. J Med Chem. 2014;57(12):5023&#x02013;38.<pub-id pub-id-type="pmid">24417533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Cucinotta</surname><given-names>D</given-names></name><name><surname>Vanelli</surname><given-names>M</given-names></name></person-group><article-title>WHO Declares COVID-19 a Pandemic</article-title><source>Acta Biomed</source><year>2020</year><volume>91</volume><issue>1</issue><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">32191675</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157&#x02013;60.<pub-id pub-id-type="pmid">32191675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><mixed-citation publication-type="other">Dai Z, et al. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight. 2021;6(7):e2108082118. 10.1073/pnas.2108082118. PMID: 34261794; PMCID: PMC8307690.</mixed-citation></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Damera</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Sachdev</surname><given-names>GP</given-names></name></person-group><article-title>IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling</article-title><source>Respir Res</source><year>2006</year><volume>7</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-7-39</pub-id><pub-id pub-id-type="pmid">16551361</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Damera G, Xia B, Sachdev GP. IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir Res. 2006;7(1):39.<pub-id pub-id-type="pmid">16551361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>de Castro</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Insights into disease resilience and longevity: Hints from COVID-19 recovered nonagenarians and centenarians</article-title><source>Gene</source><year>2025</year><volume>934</volume><fpage>149025</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2024.149025</pub-id><pub-id pub-id-type="pmid">39437899</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">de Castro MV, et al. Insights into disease resilience and longevity: Hints from COVID-19 recovered nonagenarians and centenarians. Gene. 2025;934:149025.<pub-id pub-id-type="pmid">39437899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Dendrou</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</article-title><source>Sci Transl Med</source><year>2016</year><volume>8</volume><issue>363</issue><fpage>363ra149</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aag1974</pub-id><pub-id pub-id-type="pmid">27807284</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Dendrou CA, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149.<pub-id pub-id-type="pmid">27807284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Downes</surname><given-names>CEJ</given-names></name><etal/></person-group><article-title>Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia</article-title><source>NPJ Precis Oncol</source><year>2021</year><volume>5</volume><issue>1</issue><fpage>75</fpage><pub-id pub-id-type="doi">10.1038/s41698-021-00215-x</pub-id><pub-id pub-id-type="pmid">34376782</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Downes CEJ, et al. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. NPJ Precis Oncol. 2021;5(1):75.<pub-id pub-id-type="pmid">34376782</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Elbadry</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Unusual pattern of thrombotic events in young adult non-critically ill patients with COVID-19 may result from an undiagnosed inherited and acquired form of thrombophilia</article-title><source>Br J Haematol</source><year>2022</year><volume>196</volume><issue>4</issue><fpage>902</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1111/bjh.17986</pub-id><pub-id pub-id-type="pmid">34888860</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Elbadry MI, et al. Unusual pattern of thrombotic events in young adult non-critically ill patients with COVID-19 may result from an undiagnosed inherited and acquired form of thrombophilia. Br J Haematol. 2022;196(4):902&#x02013;22.<pub-id pub-id-type="pmid">34888860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Falasca</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy of canakinumab in mild or severe COVID-19 pneumonia</article-title><source>Immun Inflamm Dis</source><year>2021</year><volume>9</volume><issue>2</issue><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/iid3.400</pub-id><pub-id pub-id-type="pmid">33465283</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Falasca K, et al. Efficacy of canakinumab in mild or severe COVID-19 pneumonia. Immun Inflamm Dis. 2021;9(2):399&#x02013;405.<pub-id pub-id-type="pmid">33465283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-kappaB signaling pathway</article-title><source>Phytomedicine</source><year>2022</year><volume>95</volume><fpage>153784</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2021.153784</pub-id><pub-id pub-id-type="pmid">34785108</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Feng Y, et al. Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-kappaB signaling pathway. Phytomedicine. 2022;95:153784.<pub-id pub-id-type="pmid">34785108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrao</surname><given-names>R</given-names></name><name><surname>Lupardus</surname><given-names>PJ</given-names></name></person-group><article-title>The Janus kinase (JAK) FERM and SH2 domains: Bringing specificity to JAK&#x02013;receptor interactions</article-title><source>Front Endocrinol</source><year>2017</year><volume>8</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.3389/fendo.2017.00071</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ferrao R, Lupardus PJ. The Janus kinase (JAK) FERM and SH2 domains: Bringing specificity to JAK&#x02013;receptor interactions. Front Endocrinol. 2017;8:71.</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Forchette</surname><given-names>L</given-names></name><name><surname>Sebastian</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group><article-title>A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics</article-title><source>Curr Med Sci</source><year>2021</year><volume>41</volume><issue>6</issue><fpage>1037</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1007/s11596-021-2395-1</pub-id><pub-id pub-id-type="pmid">34241776</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci. 2021;41(6):1037&#x02013;51.<pub-id pub-id-type="pmid">34241776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>J</given-names></name><etal/></person-group><article-title>CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>347</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00760-8</pub-id><pub-id pub-id-type="pmid">34564690</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Geng J, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther. 2021;6(1):347.<pub-id pub-id-type="pmid">34564690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation</article-title><source>Science</source><year>2022</year><volume>376</volume><issue>6589</issue><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1126/science.abn8933</pub-id><pub-id pub-id-type="pmid">35271300</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Glassman CR, et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science. 2022;376(6589):163&#x02013;9.<pub-id pub-id-type="pmid">35271300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Gotthardt</surname><given-names>D</given-names></name><etal/></person-group><article-title>JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2590</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02590</pub-id><pub-id pub-id-type="pmid">31781102</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Gotthardt D, et al. JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation. Front Immunol. 2019;10:2590.<pub-id pub-id-type="pmid">31781102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Tofacitinib in patients hospitalized with Covid-19 pneumonia</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>5</issue><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101643</pub-id><pub-id pub-id-type="pmid">34133856</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Guimaraes PO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406&#x02013;15.<pub-id pub-id-type="pmid">34133856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19</article-title><source>Genome Med</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s13073-022-01049-3</pub-id><pub-id pub-id-type="pmid">35501841</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Guo C, et al. Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19. Genome Med. 2022;14(1):46.<pub-id pub-id-type="pmid">35501841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>V</given-names></name><etal/></person-group><article-title>Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>13</issue><fpage>1207</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2118691</pub-id><pub-id pub-id-type="pmid">35172051</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hall V, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207&#x02013;20.<pub-id pub-id-type="pmid">35172051</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Hammersen</surname><given-names>J</given-names></name><etal/></person-group><article-title>The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial</article-title><source>Leukemia</source><year>2023</year><volume>37</volume><issue>9</issue><fpage>1879</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1038/s41375-023-01979-w</pub-id><pub-id pub-id-type="pmid">37507425</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hammersen J, et al. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia. 2023;37(9):1879&#x02013;86.<pub-id pub-id-type="pmid">37507425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Rheumatol</source><year>2022</year><volume>4</volume><issue>5</issue><fpage>e351</fpage><lpage>e361</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(22)00044-3</pub-id><pub-id pub-id-type="pmid">35368384</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Han MK, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022;4(5):e351&#x02013;61.<pub-id pub-id-type="pmid">35368384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>P</given-names></name><etal/></person-group><article-title>Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)</article-title><source>Br J Haematol</source><year>2021</year><volume>193</volume><issue>4</issue><fpage>692</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1111/bjh.17402</pub-id><pub-id pub-id-type="pmid">33719038</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Harrington P, et al. Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Br J Haematol. 2021;193(4):692&#x02013;6.<pub-id pub-id-type="pmid">33719038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselbalch</surname><given-names>HC</given-names></name><etal/></person-group><article-title>COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon</article-title><source>Cytokine Growth Factor Rev</source><year>2021</year><volume>60</volume><fpage>28</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2021.03.006</pub-id><pub-id pub-id-type="pmid">33992887</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hasselbalch HC, et al. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev. 2021;60:28&#x02013;45.<pub-id pub-id-type="pmid">33992887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Protein kinase C inhibitors reduce SARS-CoV-2 replication in cultured cells</article-title><source>Microbiol Spectr</source><year>2022</year><volume>10</volume><issue>5</issue><fpage>e0105622</fpage><pub-id pub-id-type="doi">10.1128/spectrum.01056-22</pub-id><pub-id pub-id-type="pmid">36000889</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Huang C, et al. Protein kinase C inhibitors reduce SARS-CoV-2 replication in cultured cells. Microbiol Spectr. 2022;10(5):e0105622.<pub-id pub-id-type="pmid">36000889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Indari</surname><given-names>O</given-names></name><etal/></person-group><article-title>An update on antiviral therapy against SARS-CoV-2: how far have we come?</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>632677</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.632677</pub-id><pub-id pub-id-type="pmid">33762954</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Indari O, et al. An update on antiviral therapy against SARS-CoV-2: how far have we come? Front Pharmacol. 2021;12:632677.<pub-id pub-id-type="pmid">33762954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>CF</given-names></name><name><surname>Eldering</surname><given-names>E</given-names></name><name><surname>Kater</surname><given-names>AP</given-names></name></person-group><article-title>Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19</article-title><source>Blood Adv</source><year>2021</year><volume>5</volume><issue>3</issue><fpage>913</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003768</pub-id><pub-id pub-id-type="pmid">33560402</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 2021;5(3):913&#x02013;25.<pub-id pub-id-type="pmid">33560402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1135145</fpage><pub-id pub-id-type="doi">10.3389/fphar.2023.1135145</pub-id><pub-id pub-id-type="pmid">37021053</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Jain NK, et al. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. Front Pharmacol. 2023;14:1135145.<pub-id pub-id-type="pmid">37021053</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic and observational associations of lung function with gastrointestinal tract diseases: pleiotropic and mendelian randomization analysis</article-title><source>Respir Res</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>315</fpage><pub-id pub-id-type="doi">10.1186/s12931-023-02621-0</pub-id><pub-id pub-id-type="pmid">38102678</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Jiang M, et al. Genetic and observational associations of lung function with gastrointestinal tract diseases: pleiotropic and mendelian randomization analysis. Respir Res. 2023;24(1):315.<pub-id pub-id-type="pmid">38102678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalil</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>9</issue><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2031994</pub-id><pub-id pub-id-type="pmid">33306283</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Kalil AC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795&#x02013;807.<pub-id pub-id-type="pmid">33306283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>1</issue><fpage>149</fpage><lpage>168 e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Karki R, et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149-168 e17.<pub-id pub-id-type="pmid">33278357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis</article-title><source>Blood</source><year>2024</year><volume>143</volume><issue>23</issue><fpage>2386</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1182/blood.2023021046</pub-id><pub-id pub-id-type="pmid">38446698</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Keenan C, et al. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis. Blood. 2024;143(23):2386&#x02013;400.<pub-id pub-id-type="pmid">38446698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Khaledi</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy</article-title><source>Front Med</source><year>2022</year><volume>9</volume><fpage>961027</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.961027</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Khaledi M, et al. COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Front Med. 2022;9:961027.</mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa</article-title><source>NEJM Evid</source><year>2024</year><volume>3</volume><issue>3</issue><fpage>EVIDoa2300155</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2300155</pub-id><pub-id pub-id-type="pmid">38335032</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kimball AB, et al. Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa. NEJM Evid. 2024;3(3):EVIDoa2300155.<pub-id pub-id-type="pmid">38335032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Koppikar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</article-title><source>Nature</source><year>2012</year><volume>489</volume><issue>7414</issue><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1038/nature11303</pub-id><pub-id pub-id-type="pmid">22820254</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Koppikar P, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489(7414):155&#x02013;9.<pub-id pub-id-type="pmid">22820254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kosmicki</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Genetic risk factors for COVID-19 and influenza are largely distinct</article-title><source>Nat Genet</source><year>2024</year><volume>56</volume><issue>8</issue><fpage>1592</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1038/s41588-024-01844-1</pub-id><pub-id pub-id-type="pmid">39103650</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kosmicki JA, et al. Genetic risk factors for COVID-19 and influenza are largely distinct. Nat Genet. 2024;56(8):1592&#x02013;6.<pub-id pub-id-type="pmid">39103650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Janus kinase inhibitors for the treatment of COVID-19</article-title><source>Cochrane Database Syst Rev</source><year>2022</year><volume>6</volume><issue>6</issue><fpage>CD015209</fpage><pub-id pub-id-type="pmid">35695334</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kramer A, et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;6(6):CD015209.<pub-id pub-id-type="pmid">35695334</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><issue>42</issue><fpage>30341</fpage><lpage>30345</lpage><pub-id pub-id-type="doi">10.1074/jbc.C600319200</pub-id><pub-id pub-id-type="pmid">17537734</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kumar N, et al. Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin. J Biol Chem. 2007;282(42):30341&#x02013;5.<pub-id pub-id-type="pmid">17537734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mucosal epithelial Jak kinases in health and diseases</article-title><source>Mediators Inflamm</source><year>2021</year><volume>2021</volume><fpage>6618924</fpage><pub-id pub-id-type="doi">10.1155/2021/6618924</pub-id><pub-id pub-id-type="pmid">33814980</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Kumar N, et al. Mucosal epithelial Jak kinases in health and diseases. Mediators Inflamm. 2021;2021:6618924.<pub-id pub-id-type="pmid">33814980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>M</given-names></name><etal/></person-group><article-title>A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies</article-title><source>J Biomed Sci</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/s12929-022-00852-9</pub-id><pub-id pub-id-type="pmid">36096815</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kumari M, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci. 2022;29(1):68.<pub-id pub-id-type="pmid">36096815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><mixed-citation publication-type="other">Kumar P, Mishra J, Kumar N. Mechanistic role of Jak3 in obesity-associated cognitive impairments. Nutrients. 2022;14(18):3715. 10.3390/nu14183715. PMID: 36145091; PMCID: PMC9505565.</mixed-citation></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>JKW</given-names></name><etal/></person-group><article-title>Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>160</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.10.018</pub-id><pub-id pub-id-type="pmid">33137363</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Lam JKW, et al. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Adv Drug Deliv Rev. 2020;160:234&#x02013;43.<pub-id pub-id-type="pmid">33137363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Leaf</surname><given-names>DE</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Tocilizumab in Covid-19</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>1</issue><fpage>86</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2032911</pub-id><pub-id pub-id-type="pmid">33356049</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Leaf DE, Gupta S, Wang W. Tocilizumab in Covid-19. N Engl J Med. 2021;384(1):86&#x02013;7.<pub-id pub-id-type="pmid">33356049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Lebwohl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials</article-title><source>Br J Dermatol</source><year>2024</year><volume>190</volume><issue>5</issue><fpage>668</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1093/bjd/ljae014</pub-id><pub-id pub-id-type="pmid">38226713</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Lebwohl M, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190(5):668&#x02013;79.<pub-id pub-id-type="pmid">38226713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><mixed-citation publication-type="other">Lee HK, Jung O, Hennighausen L. Activation of interferon-stimulated transcriptomes and ACE2 isoforms in human airway epithelium is curbed by Janus kinase inhibitors. Res Square. 2020.Dec 11:rs.3.rs-119695. doi: 10.21203/rs.3.rs-119695/v1. Update in: Commun Biol. 2021 Jun 2;4(1):654. doi: 10.1038/s42003-021-02167-1. PMID: 33330857; PMCID: PMC7743079</mixed-citation></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Jung</surname><given-names>O</given-names></name><name><surname>Hennighausen</surname><given-names>L</given-names></name></person-group><article-title>JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells</article-title><source>Commun Biol</source><year>2021</year><volume>4</volume><issue>1</issue><fpage>654</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02167-1</pub-id><pub-id pub-id-type="pmid">34079039</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Lee HK, Jung O, Hennighausen L. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021;4(1):654.<pub-id pub-id-type="pmid">34079039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><mixed-citation publication-type="other">Levy G, et al. JAK inhibitors and COVID-19. J Immunother Cancer. 2022;10(4):e002838. 10.1136/jitc-2021-002838. Erratum in: J Immunother Cancer. 2023;11(4):e002838corr1. 10.1136/jitc-2021-002838corr1. PMID: 35459733; PMCID: PMC9035837.</mixed-citation></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis</article-title><source>Dermatology</source><year>2022</year><volume>238</volume><issue>4</issue><fpage>725</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1159/000518541</pub-id><pub-id pub-id-type="pmid">34455413</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Li C, et al. Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology. 2022;238(4):725&#x02013;35.<pub-id pub-id-type="pmid">34455413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cytokine storm and translating IL-6 biology into effective treatments for COVID-19</article-title><source>Front Med</source><year>2023</year><volume>17</volume><issue>6</issue><fpage>1080</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1007/s11684-023-1044-4</pub-id><pub-id pub-id-type="pmid">38157195</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Li T, et al. Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Front Med. 2023;17(6):1080&#x02013;95.<pub-id pub-id-type="pmid">38157195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19)</article-title><source>Aging (Albany NY)</source><year>2021</year><volume>13</volume><issue>4</issue><fpage>4811</fpage><lpage>4830</lpage><pub-id pub-id-type="doi">10.18632/aging.202622</pub-id><pub-id pub-id-type="pmid">33581688</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Li X, et al. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19). Aging (Albany NY). 2021;13(4):4811&#x02013;30.<pub-id pub-id-type="pmid">33581688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>F</given-names></name><etal/></person-group><article-title>JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>86</volume><fpage>106706</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106706</pub-id><pub-id pub-id-type="pmid">32570038</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Liang F, et al. JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. Int Immunopharmacol. 2020;86:106706.<pub-id pub-id-type="pmid">32570038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma</article-title><source>Drug Resist Updat</source><year>2023</year><volume>68</volume><fpage>100957</fpage><pub-id pub-id-type="doi">10.1016/j.drup.2023.100957</pub-id><pub-id pub-id-type="pmid">36990047</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Liang Q, et al. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma. Drug Resist Updat. 2023;68:100957.<pub-id pub-id-type="pmid">36990047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma</article-title><source>J Adv Res</source><year>2022</year><volume>40</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2021.11.016</pub-id><pub-id pub-id-type="pmid">36100323</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Long Q, et al. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. J Adv Res. 2022;40:153&#x02013;66.<pub-id pub-id-type="pmid">36100323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez Bernal</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>7</issue><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2108891</pub-id><pub-id pub-id-type="pmid">34289274</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Lopez Bernal J, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585&#x02013;94.<pub-id pub-id-type="pmid">34289274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Lucijanic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism</article-title><source>Blood Cancer J</source><year>2021</year><volume>11</volume><issue>11</issue><fpage>189</fpage><pub-id pub-id-type="doi">10.1038/s41408-021-00585-2</pub-id><pub-id pub-id-type="pmid">34845183</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Lucijanic M, et al. Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism. Blood Cancer J. 2021;11(11):189.<pub-id pub-id-type="pmid">34845183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><etal/></person-group><article-title>The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2</article-title><source>Gene</source><year>2021</year><volume>768</volume><fpage>145325</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2020.145325</pub-id><pub-id pub-id-type="pmid">33253796</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.<pub-id pub-id-type="pmid">33253796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><etal/></person-group><article-title>Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19</article-title><source>Trends Pharmacol Sci</source><year>2020</year><volume>41</volume><issue>8</issue><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.06.007</pub-id><pub-id pub-id-type="pmid">32580895</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Luo W, et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531&#x02013;43.<pub-id pub-id-type="pmid">32580895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahjoor</surname><given-names>M</given-names></name><etal/></person-group><article-title>Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy</article-title><source>Cell Commun Signal</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>272</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01240-y</pub-id><pub-id pub-id-type="pmid">37784164</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Mahjoor M, et al. Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy. Cell Commun Signal. 2023;21(1):272.<pub-id pub-id-type="pmid">37784164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Marconi</surname><given-names>VC</given-names></name><etal/></person-group><article-title>Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial</article-title><source>Lancet Respir Med</source><year>2021</year><volume>9</volume><issue>12</issue><fpage>1407</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00331-3</pub-id><pub-id pub-id-type="pmid">34480861</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407&#x02013;18.<pub-id pub-id-type="pmid">34480861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Maslennikov</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19</article-title><source>Pulm Pharmacol Ther</source><year>2021</year><volume>69</volume><fpage>102039</fpage><pub-id pub-id-type="doi">10.1016/j.pupt.2021.102039</pub-id><pub-id pub-id-type="pmid">34023513</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Maslennikov R, et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039.<pub-id pub-id-type="pmid">34023513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>An aberrant STAT pathway is central to COVID-19</article-title><source>Cell Death Differ</source><year>2020</year><volume>27</volume><issue>12</issue><fpage>3209</fpage><lpage>3225</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00633-7</pub-id><pub-id pub-id-type="pmid">33037393</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Matsuyama T, et al. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27(12):3209&#x02013;25.<pub-id pub-id-type="pmid">33037393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>McGee</surname><given-names>MC</given-names></name><name><surname>August</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy</article-title><source>J Leukoc Biol</source><year>2021</year><volume>109</volume><issue>1</issue><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/JLB.5COVR0620-306R</pub-id><pub-id pub-id-type="pmid">32640487</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">McGee MC, August A, Huang W. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy. J Leukoc Biol. 2021;109(1):49&#x02013;53.<pub-id pub-id-type="pmid">32640487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><etal/></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x02013;4.<pub-id pub-id-type="pmid">32192578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>LK</given-names></name><etal/></person-group><article-title>JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>6</issue><fpage>657</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1182/blood.2020006075</pub-id><pub-id pub-id-type="pmid">32530039</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Meyer LK, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020;136(6):657&#x02013;68.<pub-id pub-id-type="pmid">32530039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Adapter protein Shc regulates Janus kinase 3 phosphorylation</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><issue>23</issue><fpage>15951</fpage><lpage>15956</lpage><pub-id pub-id-type="doi">10.1074/jbc.C113.527523</pub-id><pub-id pub-id-type="pmid">24795043</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Mishra J, Kumar N. Adapter protein Shc regulates Janus kinase 3 phosphorylation. J Biol Chem. 2014;289(23):15951&#x02013;6.<pub-id pub-id-type="pmid">24795043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Waters</surname><given-names>CM</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Molecular mechanism of interleukin-2-induced mucosal homeostasis</article-title><source>Am J Physiol Cell Physiol</source><year>2012</year><volume>302</volume><issue>5</issue><fpage>C735</fpage><lpage>C747</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00316.2011</pub-id><pub-id pub-id-type="pmid">22116305</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Mishra J, Waters CM, Kumar N. Molecular mechanism of interleukin-2-induced mucosal homeostasis. Am J Physiol Cell Physiol. 2012;302(5):C735&#x02013;47.<pub-id pub-id-type="pmid">22116305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><issue>44</issue><fpage>31795</fpage><lpage>31806</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.504126</pub-id><pub-id pub-id-type="pmid">24045942</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Mishra J, et al. Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis. J Biol Chem. 2013;288(44):31795&#x02013;806.<pub-id pub-id-type="pmid">24045942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Das</surname><given-names>JK</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through beta-catenin</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><issue>40</issue><fpage>16406</fpage><lpage>16419</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.811802</pub-id><pub-id pub-id-type="pmid">28821617</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Mishra J, Das JK, Kumar N. Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through beta-catenin. J Biol Chem. 2017;292(40):16406&#x02013;19.<pub-id pub-id-type="pmid">28821617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Simonsen</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity</article-title><source>J Biol Chem</source><year>2019</year><volume>294</volume><issue>48</issue><fpage>18337</fpage><lpage>18348</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.007758</pub-id><pub-id pub-id-type="pmid">31653704</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Mishra J, Simonsen R, Kumar N. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity. J Biol Chem. 2019;294(48):18337&#x02013;48.<pub-id pub-id-type="pmid">31653704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><mixed-citation publication-type="other">Momen YS, Mishra J, Kumar N. Brain-gut and microbiota-gut-brain communication in Type-2 diabetes linked Alzheimer's disease. Nutrients. 2024;16(15):2558. 10.3390/nu16152558. PMID: 39125436; PMCID: PMC11313915.</mixed-citation></ref><ref id="CR89"><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Murugesan</surname><given-names>H</given-names></name><etal/></person-group><article-title>An Evaluation of efficacy and safety of Tofacitinib, A JAK inhibitor in the management of hospitalized patients with mild to moderate COVID-19 - an open-label randomized controlled study</article-title><source>J Assoc Physicians India</source><year>2022</year><volume>69</volume><issue>12</issue><fpage>11</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">35057599</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Murugesan H, et al. An Evaluation of efficacy and safety of Tofacitinib, A JAK inhibitor in the management of hospitalized patients with mild to moderate COVID-19 - an open-label randomized controlled study. J Assoc Physicians India. 2022;69(12):11&#x02013;2.<pub-id pub-id-type="pmid">35057599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>806568</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.806568</pub-id><pub-id pub-id-type="pmid">35444538</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Naik RR, et al. Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Front Pharmacol. 2022;13:806568.<pub-id pub-id-type="pmid">35444538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Parvathaneni</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name></person-group><article-title>Utilizing drug repurposing against COVID-19 - efficacy, limitations, and challenges</article-title><source>Life Sci</source><year>2020</year><volume>259</volume><fpage>118275</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118275</pub-id><pub-id pub-id-type="pmid">32818545</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Parvathaneni V, Gupta V. Utilizing drug repurposing against COVID-19 - efficacy, limitations, and challenges. Life Sci. 2020;259:118275.<pub-id pub-id-type="pmid">32818545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Pelkey</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Coexistence of chronic myelomonocytic leukemia and ulcerative colitis with rapid progression to acute myelomonocytic leukemia: a case report</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>2</issue><fpage>e22422</fpage><pub-id pub-id-type="pmid">35228982</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Pelkey LJ, et al. Coexistence of chronic myelomonocytic leukemia and ulcerative colitis with rapid progression to acute myelomonocytic leukemia: a case report. Cureus. 2022;14(2):e22422.<pub-id pub-id-type="pmid">35228982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Piccirillo</surname><given-names>MC</given-names></name><etal/></person-group><article-title>TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia</article-title><source>Study Protocol Contemp Clin Trials</source><year>2020</year><volume>98</volume><fpage>106165</fpage><pub-id pub-id-type="doi">10.1016/j.cct.2020.106165</pub-id><pub-id pub-id-type="pmid">33031955</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Piccirillo MC, et al. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study Protocol Contemp Clin Trials. 2020;98:106165.<pub-id pub-id-type="pmid">33031955</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Pilz</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity</article-title><source>Environ Res</source><year>2022</year><volume>209</volume><fpage>112911</fpage><pub-id pub-id-type="doi">10.1016/j.envres.2022.112911</pub-id><pub-id pub-id-type="pmid">35149106</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Pilz S, et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911.<pub-id pub-id-type="pmid">35149106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Portsmore</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer</article-title><source>Br J Haematol</source><year>2020</year><volume>190</volume><issue>4</issue><fpage>525</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1111/bjh.16966</pub-id><pub-id pub-id-type="pmid">32584421</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Portsmore S, et al. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer. Br J Haematol. 2020;190(4):525&#x02013;8.<pub-id pub-id-type="pmid">32584421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Que</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality</article-title><source>Int Rev Immunol</source><year>2022</year><volume>41</volume><issue>2</issue><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1080/08830185.2021.1884248</pub-id><pub-id pub-id-type="pmid">33616462</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Que Y, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2022;41(2):217&#x02013;30.<pub-id pub-id-type="pmid">33616462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Quero</surname><given-names>L</given-names></name><etal/></person-group><article-title>miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>3087</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.03087</pub-id><pub-id pub-id-type="pmid">32047494</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Quero L, et al. miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation. Front Immunol. 2019;10:3087.<pub-id pub-id-type="pmid">32047494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Ragab</surname><given-names>D</given-names></name><etal/></person-group><article-title>The COVID-19 cytokine storm; what we know so far</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1446</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01446</pub-id><pub-id pub-id-type="pmid">32612617</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Ragab D, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.<pub-id pub-id-type="pmid">32612617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><mixed-citation publication-type="other">Raivola J, Haikarainen T, Silvennoinen O. Characterization of JAK1 Pseudokinase domain in cytokine signaling. Cancers (Basel). 2019;12(1).:78. doi: 10.3390/cancers12010078. PMID: 31892268; PMCID: PMC7016850</mixed-citation></ref><ref id="CR100"><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Evolutionary, comparative, and functional analyses of STATs and regulation of the JAK-STAT pathway in lumpfish upon bacterial and poly(I:C) exposure</article-title><source>Front Cell Infect Microbiol</source><year>2023</year><volume>13</volume><fpage>1252744</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2023.1252744</pub-id><pub-id pub-id-type="pmid">37808912</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Rao SS, et al. Evolutionary, comparative, and functional analyses of STATs and regulation of the JAK-STAT pathway in lumpfish upon bacterial and poly(I:C) exposure. Front Cell Infect Microbiol. 2023;13:1252744.<pub-id pub-id-type="pmid">37808912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Rarani</surname><given-names>FZ</given-names></name><etal/></person-group><article-title>Cytokines and microRNAs in SARS-CoV-2: what do we know?</article-title><source>Molecular Therapy-Nucleic Acids</source><year>2022</year><volume>29</volume><fpage>219</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.06.017</pub-id><pub-id pub-id-type="pmid">35782361</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Rarani FZ, et al. Cytokines and microRNAs in SARS-CoV-2: what do we know? Molecular Therapy-Nucleic Acids. 2022;29:219&#x02013;42.<pub-id pub-id-type="pmid">35782361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Rincon-Arevalo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Altered increase in STAT1 expression and phosphorylation in severe COVID-19</article-title><source>Eur J Immunol</source><year>2022</year><volume>52</volume><issue>1</issue><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1002/eji.202149575</pub-id><pub-id pub-id-type="pmid">34676541</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Rincon-Arevalo H, et al. Altered increase in STAT1 expression and phosphorylation in severe COVID-19. Eur J Immunol. 2022;52(1):138&#x02013;48.<pub-id pub-id-type="pmid">34676541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Rommasi</surname><given-names>F</given-names></name><name><surname>Nasiri</surname><given-names>MJ</given-names></name><name><surname>Mirsaeidi</surname><given-names>M</given-names></name></person-group><article-title>Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features</article-title><source>Mol Cell Biochem</source><year>2022</year><volume>477</volume><issue>3</issue><fpage>711</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1007/s11010-021-04325-9</pub-id><pub-id pub-id-type="pmid">35013850</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Rommasi F, Nasiri MJ, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Mol Cell Biochem. 2022;477(3):711&#x02013;26.<pub-id pub-id-type="pmid">35013850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosas</surname><given-names>IO</given-names></name><etal/></person-group><article-title>Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>16</issue><fpage>1503</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2028700</pub-id><pub-id pub-id-type="pmid">33631066</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Rosas IO, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503&#x02013;16.<pub-id pub-id-type="pmid">33631066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><mixed-citation publication-type="other">Roschewski M, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48).:eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5. PMID: 32503877; PMCID: PMC7274761</mixed-citation></ref><ref id="CR106"><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Macrophage activation syndrome and COVID 19: impact of MAPK driven immune-epigenetic programming by SARS-Cov-2</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>763313</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.763313</pub-id><pub-id pub-id-type="pmid">34659270</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Roy RK, et al. Macrophage activation syndrome and COVID 19: impact of MAPK driven immune-epigenetic programming by SARS-Cov-2. Front Immunol. 2021;12:763313.<pub-id pub-id-type="pmid">34659270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Samavati</surname><given-names>L</given-names></name><name><surname>Uhal</surname><given-names>BD</given-names></name></person-group><article-title>ACE2, much more than just a receptor for SARS-COV-2</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>317</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00317</pub-id><pub-id pub-id-type="pmid">32582574</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.<pub-id pub-id-type="pmid">32582574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanachai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Insights into the binding recognition and susceptibility of tofacitinib toward Janus kinases</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><issue>1</issue><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1021/acsomega.9b02800</pub-id><pub-id pub-id-type="pmid">31956784</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Sanachai K, et al. Insights into the binding recognition and susceptibility of tofacitinib toward Janus kinases. ACS Omega. 2020;5(1):369&#x02013;77.<pub-id pub-id-type="pmid">31956784</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarmiento</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids</article-title><source>Acta Haematol</source><year>2021</year><volume>144</volume><issue>6</issue><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1159/000516464</pub-id><pub-id pub-id-type="pmid">34111867</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Sarmiento M, et al. Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids. Acta Haematol. 2021;144(6):620&#x02013;6.<pub-id pub-id-type="pmid">34111867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Satarker</surname><given-names>S</given-names></name><etal/></person-group><article-title>JAK-STAT Pathway inhibition and their implications in COVID-19 Therapy</article-title><source>Postgrad Med</source><year>2021</year><volume>133</volume><issue>5</issue><fpage>489</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1080/00325481.2020.1855921</pub-id><pub-id pub-id-type="pmid">33245005</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Satarker S, et al. JAK-STAT Pathway inhibition and their implications in COVID-19 Therapy. Postgrad Med. 2021;133(5):489&#x02013;507.<pub-id pub-id-type="pmid">33245005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Shanker</surname><given-names>OR</given-names></name><etal/></person-group><article-title>Role of non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets</article-title><source>Expert Opin Ther Targets</source><year>2024</year><volume>28</volume><issue>4</issue><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1080/14728222.2024.2343952</pub-id><pub-id pub-id-type="pmid">38629385</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Shanker OR, et al. Role of non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets. Expert Opin Ther Targets. 2024;28(4):283&#x02013;94.<pub-id pub-id-type="pmid">38629385</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>T</given-names></name><etal/></person-group><article-title>The gut ecosystem and immune tolerance</article-title><source>J Autoimmun</source><year>2023</year><volume>141</volume><fpage>103114</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2023.103114</pub-id><pub-id pub-id-type="pmid">37748979</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Shao T, et al. The gut ecosystem and immune tolerance. J Autoimmun. 2023;141:103114.<pub-id pub-id-type="pmid">37748979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name><etal/></person-group><article-title>An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19</article-title><source>Diabetes Metab Syndr</source><year>2022</year><volume>16</volume><issue>2</issue><fpage>102396</fpage><pub-id pub-id-type="doi">10.1016/j.dsx.2022.102396</pub-id><pub-id pub-id-type="pmid">35051686</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Singh AK, et al. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022;16(2):102396.<pub-id pub-id-type="pmid">35051686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><mixed-citation publication-type="other">Singh D, et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. Eur Respir J. 2021;58(4):2100673. 10.1183/13993003.00673-2021. PMID: 34210790; PMCID: PMC8859971.</mixed-citation></ref><ref id="CR115"><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>MK</given-names></name><etal/></person-group><article-title>A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection?</article-title><source>Comput Biol Med</source><year>2021</year><volume>130</volume><fpage>104219</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104219</pub-id><pub-id pub-id-type="pmid">33486379</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Singh MK, et al. A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med. 2021;130:104219.<pub-id pub-id-type="pmid">33486379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>L</given-names></name><etal/></person-group><article-title>COVID-19, an Opportunity for developing countries?</article-title><source>Front Public Health</source><year>2020</year><volume>8</volume><fpage>548708</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2020.548708</pub-id><pub-id pub-id-type="pmid">33330304</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Smith L, et al. COVID-19, an Opportunity for developing countries? Front Public Health. 2020;8:548708.<pub-id pub-id-type="pmid">33330304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Use of Baricitinib in combination with remdesivir and steroid in COVID-19 treatment: a multicenter retrospective study</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>12</issue><fpage>e20620</fpage><pub-id pub-id-type="pmid">35106192</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">So JM, et al. Use of Baricitinib in combination with remdesivir and steroid in COVID-19 treatment: a multicenter retrospective study. Cureus. 2021;13(12):e20620.<pub-id pub-id-type="pmid">35106192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Solis Arce</surname><given-names>JS</given-names></name><etal/></person-group><article-title>COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><issue>8</issue><fpage>1385</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01454-y</pub-id><pub-id pub-id-type="pmid">34272499</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Solis Arce JS, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385&#x02013;94.<pub-id pub-id-type="pmid">34272499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonkar</surname><given-names>C</given-names></name><etal/></person-group><article-title>Repurposing of gastric cancer drugs against COVID-19</article-title><source>Comput Biol Med</source><year>2021</year><volume>137</volume><fpage>104826</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104826</pub-id><pub-id pub-id-type="pmid">34537409</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Sonkar C, et al. Repurposing of gastric cancer drugs against COVID-19. Comput Biol Med. 2021;137:104826.<pub-id pub-id-type="pmid">34537409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Sparks</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry</article-title><source>Ann Rheum Dis</source><year>2021</year><volume>80</volume><issue>9</issue><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2021-220418</pub-id><pub-id pub-id-type="pmid">34049860</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Sparks JA, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137&#x02013;46.<pub-id pub-id-type="pmid">34049860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><mixed-citation publication-type="other">Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol. 2020;5(47).:eabc5367. doi: 10.1126/sciimmunol.abc5367. PMID: 32385052</mixed-citation></ref><ref id="CR122"><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach</article-title><source>Nat Rev Rheumatol</source><year>2022</year><volume>18</volume><issue>3</issue><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41584-021-00726-8</pub-id><pub-id pub-id-type="pmid">34987201</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Tanaka Y, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133&#x02013;45.<pub-id pub-id-type="pmid">34987201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia</article-title><source>Inflammation and Regeneration</source><year>2023</year><volume>43</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s41232-022-00253-3</pub-id><pub-id pub-id-type="pmid">36617565</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Tanaka Y. A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. Inflammation and Regeneration. 2023;43(1):3.<pub-id pub-id-type="pmid">36617565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Gangat</surname><given-names>N</given-names></name></person-group><article-title>Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis</article-title><source>Haematologica</source><year>2023</year><volume>108</volume><issue>11</issue><fpage>2919</fpage><lpage>2932</lpage><pub-id pub-id-type="doi">10.3324/haematol.2022.282612</pub-id><pub-id pub-id-type="pmid">36861402</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica. 2023;108(11):2919&#x02013;32.<pub-id pub-id-type="pmid">36861402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>4</issue><fpage>320</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107058</pub-id><pub-id pub-id-type="pmid">34192428</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Thompson MG, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021;385(4):320&#x02013;9.<pub-id pub-id-type="pmid">34192428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>NV</given-names></name><etal/></person-group><article-title>Potent and selective knockdown of tyrosine kinase 2 by antisense oligonucleotides</article-title><source>Immunohorizons</source><year>2021</year><volume>5</volume><issue>2</issue><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.4049/immunohorizons.2000108</pub-id><pub-id pub-id-type="pmid">33542028</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Tran NV, et al. Potent and selective knockdown of tyrosine kinase 2 by antisense oligonucleotides. Immunohorizons. 2021;5(2):70&#x02013;80.<pub-id pub-id-type="pmid">33542028</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Ucciferri</surname><given-names>C</given-names></name><name><surname>Vecchiet</surname><given-names>J</given-names></name><name><surname>Falasca</surname><given-names>K</given-names></name></person-group><article-title>Role of monoclonal antibody drugs in the treatment of COVID-19</article-title><source>World J Clin Cases</source><year>2020</year><volume>8</volume><issue>19</issue><fpage>4280</fpage><lpage>4285</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v8.i19.4280</pub-id><pub-id pub-id-type="pmid">33083387</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases. 2020;8(19):4280&#x02013;5.<pub-id pub-id-type="pmid">33083387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Ucciferri</surname><given-names>C</given-names></name><etal/></person-group><article-title>Canakinumab in a subgroup of patients with COVID-19</article-title><source>Lancet Rheumatol</source><year>2020</year><volume>2</volume><issue>8</issue><fpage>e457</fpage><lpage>ee458</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30167-3</pub-id><pub-id pub-id-type="pmid">32835251</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Ucciferri C, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457-ee458.<pub-id pub-id-type="pmid">32835251</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><mixed-citation publication-type="other">Vannucchi AM, et al. JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. J Clin Med. 2021;10(16):3752. 10.3390/jcm10163752. PMID: 34442045; PMCID: PMC8397012.</mixed-citation></ref><ref id="CR130"><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Walz</surname><given-names>L</given-names></name><etal/></person-group><article-title>JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis</article-title><source>BMC Infect Dis</source><year>2021</year><volume>21</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12879-020-05730-z</pub-id><pub-id pub-id-type="pmid">33390160</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Walz L, et al. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:1&#x02013;10.<pub-id pub-id-type="pmid">33390160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ruxolitinib for emergency treatment of COVID-19-associated cytokine storm: findings from an expanded access study</article-title><source>Clin Respir J</source><year>2025</year><volume>19</volume><issue>4</issue><fpage>e70050</fpage><pub-id pub-id-type="doi">10.1111/crj.70050</pub-id><pub-id pub-id-type="pmid">40197709</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Weinstein J, et al. Ruxolitinib for emergency treatment of COVID-19-associated cytokine storm: findings from an expanded access study. Clin Respir J. 2025;19(4):e70050.<pub-id pub-id-type="pmid">40197709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilk</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>A single-cell atlas of the peripheral immune response in patients with severe COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1070</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0944-y</pub-id><pub-id pub-id-type="pmid">32514174</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Wilk AJ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070&#x02013;6.<pub-id pub-id-type="pmid">32514174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evasion of Type I Interferon by SARS-CoV-2</article-title><source>Cell Rep</source><year>2020</year><volume>33</volume><issue>1</issue><fpage>108234</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108234</pub-id><pub-id pub-id-type="pmid">32979938</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Xia H, et al. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 2020;33(1):108234.<pub-id pub-id-type="pmid">32979938</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>B</given-names></name><etal/></person-group><article-title>SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation</article-title><source>Science immunology</source><year>2021</year><volume>6</volume><issue>58</issue><fpage>eabg0833</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abg0833</pub-id><pub-id pub-id-type="pmid">33827897</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Yan B, et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science immunology. 2021;6(58):eabg0833.<pub-id pub-id-type="pmid">33827897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><issue>5</issue><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><pub-id pub-id-type="pmid">32105632</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475&#x02013;81.<pub-id pub-id-type="pmid">32105632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><article-title>The pathogenesis and treatment of the; Cytokine Storm' in COVID-19</article-title><source>J Infect</source><year>2020</year><volume>80</volume><issue>6</issue><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.037</pub-id><pub-id pub-id-type="pmid">32283152</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Ye Q, Wang B, Mao J. The pathogenesis and treatment of the; Cytokine Storm&#x02019; in COVID-19. J Infect. 2020;80(6):607&#x02013;13.<pub-id pub-id-type="pmid">32283152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Human genetic and immunological determinants of critical COVID-19 pneumonia</article-title><source>Nature</source><year>2022</year><volume>603</volume><issue>7902</issue><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04447-0</pub-id><pub-id pub-id-type="pmid">35090163</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Zhang Q, et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587&#x02013;98.<pub-id pub-id-type="pmid">35090163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense</article-title><source>Immunol Rev</source><year>2008</year><volume>226</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00698.x</pub-id><pub-id pub-id-type="pmid">19161414</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008;226:29&#x02013;40.<pub-id pub-id-type="pmid">19161414</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><mixed-citation publication-type="other">Zhang Y, et al. Inhibition of the IFN-alpha JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells. Viruses. 2022;14(4):667. 10.3390/v14040667. PMID: 35458397; PMCID: PMC9032603.</mixed-citation></ref><ref id="CR140"><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mechanism of COVID-19 causing ARDS: exploring the possibility of preventing and treating SARS-CoV-2</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><fpage>931061</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2022.931061</pub-id><pub-id pub-id-type="pmid">35774402</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Zheng J, et al. Mechanism of COVID-19 causing ARDS: exploring the possibility of preventing and treating SARS-CoV-2. Front Cell Infect Microbiol. 2022;12:931061.<pub-id pub-id-type="pmid">35774402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><etal/></person-group><article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><issue>7</issue><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id><pub-id pub-id-type="pmid">33963333</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Zheng M, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22(7):829&#x02013;38.<pub-id pub-id-type="pmid">33963333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x02013;3.<pub-id pub-id-type="pmid">32015507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease</article-title><source>Nat Genet</source><year>2016</year><volume>48</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/ng.3459</pub-id><pub-id pub-id-type="pmid">26642243</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Zhou Q, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67&#x02013;73.<pub-id pub-id-type="pmid">26642243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Novel small molecule tyrosine kinase 2 pseudokinase ligands block cytokine-induced TYK2-mediated signaling pathways</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>884399</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.884399</pub-id><pub-id pub-id-type="pmid">35693820</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Zhou Y, et al. Novel small molecule tyrosine kinase 2 pseudokinase ligands block cytokine-induced TYK2-mediated signaling pathways. Front Immunol. 2022;13:884399.<pub-id pub-id-type="pmid">35693820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Zizzo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunotherapy of COVID-19: inside and beyond IL-6 signalling</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>795315</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.795315</pub-id><pub-id pub-id-type="pmid">35340805</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">Zizzo G, et al. Immunotherapy of COVID-19: inside and beyond IL-6 signalling. Front Immunol. 2022;13:795315.<pub-id pub-id-type="pmid">35340805</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>